
==== Front
Orphanet J Rare Dis
Orphanet J Rare Dis
Orphanet Journal of Rare Diseases
1750-1172
BioMed Central London

2112
10.1186/s13023-021-02112-9
Research
Overlap phenotypes of the left ventricular noncompaction and hypertrophic cardiomyopathy with complex arrhythmias and heart failure induced by the novel truncated DSC2 mutation
http://orcid.org/0000-0002-7625-3579
Lin Yubi 1
Huang Jiana 12
Zhu Zhiling 1
Zhang Zuoquan 1
Xian Jianzhong 1
Yang Zhe 1
Qin Tingfeng 3
Chen Linxi 3
Huang Jingmin 3
Huang Yin 1
Wu Qiaoyun 1
Hu Zhenyu 14
Lin Xiufang linxiufang_126@126.com

1
Xu Geyang xugeyangliang@163.com

3
1 grid.12981.33 0000 0001 2360 039X The Center of Cardiovascular Diseases, The Department of Cardiology, Radiology and Ultrasonography, Guangdong Provincial Key Laboratory of Biomedical Imaging, The Fifth Affiliated Hospital, Sun Yat-Sen University, Zhuhai, 519000 China
2 grid.12981.33 0000 0001 2360 039X Reproductive Center, The Six Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510000 China
3 grid.258164.c 0000 0004 1790 3548 Department of Physiology, The School of Medicine of Jinan University, Guangzhou, 510000 China
4 grid.4280.e 0000 0001 2180 6431 Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117593 Singapore
24 11 2021
24 11 2021
2021
16 4966 8 2021
6 11 2021
© The Author(s) 2021
https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

The left ventricular noncompaction cardiomyopathy (LVNC) is a rare subtype of cardiomyopathy associated with a high risk of heart failure (HF), thromboembolism, arrhythmia, and sudden cardiac death.

Methods

The proband with overlap phenotypes of LVNC and hypertrophic cardiomyopathy (HCM) complicates atrial fibrillation (AF), ventricular tachycardia (VT), and HF due to the diffuse myocardial lesion, which were diagnosed by electrocardiogram, echocardiogram and cardiac magnetic resonance imaging. Peripheral blood was collected from the proband and his relatives. DNA was extracted from the peripheral blood of proband for high-throughput target capture sequencing. The Sanger sequence verified the variants. The protein was extracted from the skin of the proband and healthy volunteer. The expression difference of desmocollin2 was detected by Western blot.

Results

The novel heterozygous truncated mutation (p.K47Rfs*2) of the DSC2 gene encoding an important component of desmosomes was detected by targeted capture sequencing. The western blots showed that the expressing level of functional desmocollin2 protein (~ 94kd) was lower in the proband than that in the healthy volunteer, indicating that DSC2 p.K47Rfs*2 obviously reduced the functional desmocollin2 protein expression in the proband.

Conclusion

The heterozygous DSC2 p.K47Rfs*2 remarkably and abnormally reduced the functional desmocollin2 expression, which may potentially induce the overlap phenotypes of LVNC and HCM, complicating AF, VT, and HF.

Keywords

Left ventricular noncompaction cardiomyopathy
Hypertrophic cardiomyopathy
Heart failure
desmocollin2
Desmosome
http://dx.doi.org/10.13039/100014718 Innovative Research Group Project of the National Natural Science Foundation of China 81970332 Lin Yubi the Science and Technology Project of Zhuhai 20191210E030072 Lin Yubi the Medical Science and Technology Research Project of Guangdong ProvinceA2018043 Lin Yubi issue-copyright-statement© The Author(s) 2021
==== Body
pmcIntroduction

The left ventricular noncompaction cardiomyopathy (LVNC) is a rare subtype of cardiomyopathy (CM) and is characterized by predominant left ventricular trabeculations with deep intertrabecular recesses and thinning of the compact epicardium [1]. LVNC can coexist with dilated (DCM), hypertrophic (HCM), restrictive (RCM), and arrhythmogenic cardiomyopathy (ACM) [2–4]. LVNC is an inherited cardiac disease, classified as primary genetic CM, and associated with high risks of syncope, chest pain, heart failure (HF), malignant arrhythmia, sudden cardiac death (SCD), and thromboembolism [5]. A recent systematic review illustrated that the risks of thromboembolism and ventricular arrhythmias in LVNC are similar to DCM. Additionally, LVNC has a higher incidence of HF hospitalization than DCM. The low left ventricular ejection fraction (LVEF) induced by LVNC is associated with a poor prognosis [6]. A previous genetic study indicated that the mutations of genes encoding sarcomeric proteins account for up to 30% of LVNC [7]. Other common mutations of genes encoding cytoskeletal, Z-line, and mitochondrial proteins include myosin heavy chain (MYH7), protein-binding protein C myosin (MYBPC3), tropomyosin alfa (TPM1), myocardial actin (ACTC1), troponin T (TNNT2), and cardiac troponin I. The less common mutations of genes inducing LVNC include Z-band protein mutations, such as Cypher/ZASP cytoskeleton protein, alpha-distrobrevin (DTNA), calcium transport proteins, calsequestrin, phospholamban, membrane proteins (A/C lamina), para-zinc-finger transcription factor [8], and mitochondrial enzymes. Our study identifies a proband with rare overlap phenotypes of LVNC and HCM from a Chinese Han family and explores the potential pathogenesis via genetic screening and molecular experiments.

Material and methods

Patients and clinical variables

All participants signed informed consent. All procedures performed in the study involving human participants were in accordance with the Declaration of Helsinki and ethical standards and were approved by the Medicine Ethics Committee of the Fifth Affiliated Hospital of Sun Yat-sen University (No. 2020K216-1).

In accordance with previous studies [1, 9], LVNC was diagnosed by cardiologists based on clinical presentation and interpretation of echocardiogram and cardiac magnetic resonance imaging (CMRI) results by using the Jenni and Petersen criteria, respectively [10, 11]. The LVNC diagnosis was based on the presence of an end-systolic ratio of the noncompacted layer to compacted layer above 2 (NC/C ≥ 2.0) on echocardiography [10] and/or an end-diastolic ratio between the noncompacted and compacted layer greater than 2.3/2.0 (NC/C ≥ 2.3/2.0) in the long/short-axis view of CMRI with specificity and negative predictive values of 99% [11]. The left ventricular systolic dysfunction was defined as systolic LVEF < 50% by echocardiogram [1]. The clinical assessment also included physical examination and 12-lead and Holter electrocardiograms (ECGs). The N-terminal of B-type natriuretic peptide precursor (NT-proBNP) assays was performed at a central independent laboratory using a commercially available kit (Roche Diagnostics, Mannheim, Germany). We obtained the skin and subcutaneous tissue of the upper left limb of the patient (II: 1) and healthy volunteer through small surgery and carried out molecular biological detection. The healthy volunteer was a 37-year-old male without cardiac diseases verified by ECG and echocardiogram.

CMRI

Imaging was acquired using the 1.5 T MR imaging system (MAGNETOM Aera, Siemens Healthcare, Germany) by using a 6-channel phased-array coil. After scout and reference scans, functional and geometric assessments were achieved using ECG-gated, cine steady-state-free precession images in standard long- (2-, 3-, and 4-chamber views) and short-axis orientations with full ventricle coverage from basis to apex. Left and right ventricular outflow tract cine sequences were also obtained. Cine images with a temporal resolution of approximately 40 ms were obtained. Additional pulse sequences, including T1WI and T2WI of blood-suppressed double inversion recovery fast spin-echo, were acquired in a standard location before contrast administration. Then, the dynamic enhancement was performed during the administration of 0.2 mmol/kg contrast agent (Gadovist, Bayer Healthcare, Berlin, Germany) with 50 frames. Late gadolinium-enhanced imaging was performed with 20 min delay and phase-sensitive inversion recovery sequence to detect myocardial scarring or fibrosis. CMRI analyses were performed using SigoVia (Siemens). The functional and geometric left ventricular indices, including left and right ventricular end-diastolic volumes, LVEF and right ventricular ejection fraction, indexed left ventricular compacted mass with papillary muscles, indexed left ventricular compacted and noncompacted mass, indexed left ventricular noncompacted mass, and their ratio was determined. In addition, the end-diastolic extent of compacted and noncompacted myocardium and their ratio were measured in one long axis geometry.

Collection of human specimens and target capture sequencing

Skin biopsies were collected from the upper left arm of the proband and healthy volunteer. Protein was extracted from tissues. Peripheral blood was collected from the proband and his relatives. DNA was extracted (using D3537-02#MagPure Buffy Coat DNA Midi KF Kit, Magen, Beijing, China) from the peripheral blood of proband for high-throughput target capture sequencing using Gene fragment capture chip (MGI BGI EXOME V4, Shenzhen, China) and MGIseq-2000 sequencer (MGI, Shenzhen, China). The panel of common risk genes associated with CMs and arrhythmias (Table 1) was detected in the proband (II: 1). SNPs and Indels were annotated using a pipeline, in which all insertion and deletion variants occurring at coding regions were considered damaging. Nonsynonymous SNPs were predicted using the SIFT (http://sift.jcvi.org/www/), PolyPhen-2 (Polymorphism Phenotyping v2, http://genetics.bwh.harvard.edu/pph2/), and MetaSVM [12]. Variants were classified as “pathogenic (P)”, “likely pathogenic (LP)”, “uncertain significance (US or VUS)”, “likely benign (LB)”, or “benign (B)” by using the InterVar tool [13] following the 2015 ACMG/ACP guidelines [14]. Variants in predisposing genes associated with hereditary arrhythmias and CMs were screened, and the filtering criteria were as follows: (1) same variants in the WES data; (2) missense, nonsense, insertion, and deletion variants; and (3) SNPs with minor allele frequency < 0.01 according to the SNP database of National Center. Other familial members were validated using the Sanger sequencing for potentially pathogenic genes. Details are shown in our previous research [15].Table 1 Susceptible genes of inherited cardiomyopathy and arrhythmia detected in the proband II: 1

A2M, AARS2, ABCA1, ABCC6, ABCC9, ABCD4, ABCG5, ABCG8, ACE, ACTA2, ACTC1, ACTN2, ACVRL1, AGT, AGTR1, AKAP9, AKAP10, ALPK3, AMPD1, ANK2, ANK3, APBB2, APOA2, APOB, APP, ARFGEF2, ARSA, ASPA, BAG3, BCS1L, BLM, BLMH, BMP1, BMPR2, BRAF, CACNA1C, CACNA2D1, CACNB2, CALR3, CASQ2, CAV3, CBL, CBS, CCM2, COL1A1, COL1A2, COL3A1, COL4A1, COL4A2, COL5A1, COL5A2, COX10, COX15, CRELD1, CRTAP, CRYAB, CSRP3, CST3, CTNNA3, DES, DPP6, DSC2, DSG2, DSP, DTNA, ELN, EMD, ENG, ENPP1, ERCC6, ERCC8, ESR1, EYA4, F2, F5, F7, F12, F13A1, FBN1, FKBP10, FKBP12, FKTN, FLNC, FOXRED1, GALC, GATA4, GATA6, GATAD1, GCLC, GDF1, GFAP, GHR, GJA1, GJA5, GLA, GNAI2, GPD1L, GSN, GUCY1A3, HADHB, HBB, HCFC1, HCN4, HEY2, HFE, HTRA1, IFITM5, ITGB3, ITM2B, JAG1, JAK2, JARID2, JPH2, JUP, KCNA5, KCNE1, KCNE2, KCNE3, KCNH2, KCNJ2, KCNJ5, KCNMB1, KCNQ1, KRAS,TAZ, KRIT1, LAMA4, LAMP2, LDB3, LDLR, LDLRAP1, LMBRD1, LMNA, LMX1B, LRP6, LTA, MAPT, MED13L, MEF2A, MIB1, MIB2, MIPEP, MLC1, MLYCD, MMACHC, MMADHC, MPO, MTHFR, MTR, MTRR, MYBPC3, MYH3, MYH6, MYH7, MYH11, MYL2, MYL3, MYLK2, MYOT, MYOZ2, MYPN, NEXN, NDUFA2, NDUFA9, NDUFA10, NDUFA12, NDUFAF2, NDUFAF6, NDUFS3, NDUFS4, NDUFS7, NDUFS8, NEBL, NKX2.5, NKX2.6, NNT, NONO, NOS3, NOTCH1, NPPA, NRAS, NRG1, NSD1, OBSCN, PCSK9, PDCD10, PDE4D, PDLIM3, PKD1, PKD2, PKP2, PLAU, PLEKHM2, PLN, PLP1, PlXND1, PMP22, PPIB, PRDM16, PRKAG2, PRKAR1A, PSEN1, PSEN2, PTPN11, RAF1, RASA1, RBM20, REN, RNF213, RYR2, SORL1, RPS6KA3, SCN1B, SCN3B, SCN4B, SCN5A, SDHA, SDHAF1, SDHD, SERPINE1, SERPINF1, SERPINH1, SGCD, SH2B1, SHOC2, SLC6A4, SLC25A4, SLC39A8, SMAD3, SMAD4, SMC1A, SNTA1, SOS1, SP7, SPARC, STRA6, SURF1, TBX1, TBX5, TBX20, TCAP, TGFB2, TGFB3, TGFBR1, TGFBR2, TLL1, TMEM38B, TMEM43, TMEM70, TNNC1, TNNI2, TNNI3, TNNT2, TNNT3, TPM1, TPM2, TREX1, TRPM4, TSC2, TSPYL1, TTN, TTR, VCL, VKORC1, WNT1, YWHAE, ZFPM2		

ACMG classification

According to ACMG standards and guidelines, all variants have been reclassified for interpreting sequence variants as P, LP, VUS, LB, or B [14]. The PM2 item in the ACMG classification is considered fulfilled if minor allele frequency (MAF) in relevant population databases is ≤ 0.1% [16]. The vast majority of reported pathogenic variants in arrhythmia and CM are extremely rare (MAF < 0.01%) [17]. The classification “high degree of pathogenicity” (item PVS1) should only be used for rare variants in genes where the loss of function is a well-established disease mechanism [18–20]. In the case of VUS, a rare variant classified as ambiguous does not provide molecular confirmation of a diagnosis. Still, it cannot be discarded as indicating a low risk of malignant arrhythmias for any patient, at least until additional data clarify its clinical role [21]. The VUS changed to LB due to a substantial increase of MAF seen with ongoing analysis of the global population, which notes the key role of global frequencies and its correlation with the prevalence of inherited arrhythmia and CM in the population [19]. Previous studies showed VUS rarely changed to P or LP variants [22].

Sanger sequencing

The variant of DSC2 p.I520T was screened again using Sanger sequencing (CX0020, TSINGKE Biological technology, Guangzhou, China) in the other members of the family. The mutation of DSC2 p.K47Rfs*2 was screened again using the TA cloning technique in the other familial members. The purified PCR product was directly linked with pClone007 Versatile Simple Vector (TSINGKE Biological technology, Guangzhou, China) by TA cloning technique and transformed into Escherichia coli (DH5α). The extracted plasmids were sequenced with ABI 3730XL (Applied Biosystem, USA). The primer of TA cloning sequencing was as follows: M13F-47:5′-CGCCAGGGTTTTCCCAGTCACGAC-3′. The primer designed with Primer Premier 5.0 was used and showed as follows: forward primer, 5′-AAGGCTATTAGAAAGCAGAC-3′; reverse primer 5′-ATATGACCCAGAAACAAGAA-3′.

Western blot

Tissues were homogenized on ice in the lysis buffer. After centrifugation and protein quantification, proteins were loaded onto SDS–PAGE gels and transferred onto nitrocellulose membranes. Membranes were incubated in 5% nonfat dry milk in TBST for 1 h at room temperature and incubated overnight at 4 °C with primary antibodies. Rabbit anti-DSC2 and mouse anti-β-actin antibody were purchased from Abcam Inc (Cambridge, MA). Antibodies were detected using 1:10,000 horseradish peroxidase-conjugated, donkey anti-rabbit, and donkey anti-mouse IgG (Jackson ImmunoResearch, USA). The Western blot luminol reagent was used to visualize bands corresponding to each antibody.

Results

Clinical presentation

The familial pedigree is shown in Fig. 1A. A male patient (proband, II: 1) aged 54 years was admitted to our hospital because of recurrent chest dullness and chest pain for three years and exacerbation for half a month. He suffered from poststernal chest distress and palm-sized chest pain, which were sometimes accompanied by palpitation. Symptoms usually occur during exhaustion and could be relieved after taking a break. The Holter of II: 1 (oral bisoprolol, 5 mg, once a day) showed persistent atrial fibrillation (AF) with a long RR interval of 3.95 seconds, low voltage in limb lead, and T wave inversion in leads of V4–V6 (Fig. 2A). The frequently paired premature ventricular extrasystoles (PVCs) originated from the left ventricular lateral wall (Fig. 2B), left ventricular apex (Fig. 2C), and left ventricular inflow tract (Fig. 2D). The episodes of ventricular tachycardia (VT) originated from the middle posterior septum (Fig. 2E) and lateral wall (Fig. 2F) of the left ventricle (LV). Coronary heart disease was excluded by coronary angiography. The level of NT-proBNP was 13,800.00 pg/ml (normal range: 0–125 pg/ml) during hospitalization and increased continuously during the follow-up.Fig. 1 The familial pedigree, Sanger sequencing and the change of desmocollin2 protein. A: The pedigree of the family. II: 1 (the proband) presented with LVNC and HCM, complicating AF, VT and HF. SCD: sudden cardiac death. B: Sanger sequencing of DSC2 variants in the family members. Sanger sequencing revealed that II: 1 carried two variants of DSC2 p.K47Rfs*2 and p.I520T, which were not detected in II: 2. II: 3 only carried with DSC2 p.I520T variant. C: the protein of desmocollin2 consists of several domains, including signaling peptide (S), proprotein (P), four extracellular cadherin domains (EC), extracellular anchor domain (EA), the transmembrane region (TM), the intracellular anchor (IA), as well as the intracellular cytoplasmic domain (ICS). X: the lost domains of desmocollin2 protein induced by DSC2 p.K47Rfs*2 mutation. D: conservative analysis of DSC2 p.I520

Fig. 2 The electrocardiograms of familial members

Echocardiography (Fig. 3) demonstrated the enlarged LV, thickened interventricular septum, thinning posterior wall of LV, and slightly enlarged right atrium. In addition, LV, especially the posterior and inferior walls, was hypokinetic and had an LVEF of 34%. The ratio of the non-compacted layer to compacted layer in LV was more than two folds at the end-systolic period of LV. The typical forward blood flowed from the ventricular cavity into the deep spaces between the prominent trabeculations during diastole. CMRI (Fig. 4) demonstrated that the ratio of the non-compacted layer to compacted layer at the end-diastolic period of LV was from 2.25 to 2.67. Deep recesses with slow blood flow could be seen among the trabeculae carneae, which communicated with the LV lumen, and this finding was consistent with the LVNC diagnosis. The basal segment, intermediate segment, anterior wall, and anterolateral wall of LV were thickened with increased, rough, and disorderly arranged trabeculae carneae in the subendocardial layer. The interventricular septum was thickened with a diameter of 18 mm. These changes suggested the combined phenotypes of LVNC and HCM. No apparent abnormal lipid signal deposition was observed in LV and right ventricle. II: 1 was administered with dabigatran (110 mg, orally, twice a day), fluvastatin (80 mg, orally, once each night), sakubatrovalsartan (50 mg, orally, twice a day), and trimetazidine (20 mg, orally, three times a day) for CMs, AF, VT, and HF therapy and metformin (50 mg, orally, three times a day) and carbamazin (100 mg, orally, once a day) for diabetes mellitus therapy since 10 years ago. II: 1 had the indication for implantable intracardiac defibrillator but refused implantation.Fig. 3 Echocardiographic characteristics of the proband II: 1. A To quantify the extent of noncompaction at the site of maximal wall thickness. The end-systolic ratio of noncompacted to compacted thickness was determined. The two layers were best visualized at end-systole as shown in this long-axis view (N, non-compacted layer; C, compacted layer). B, C Color Doppler study showed typical forward blood flow from the ventricular cavity into the deep spaces between the prominent trabeculations during diastole (in B represented by a red signal). Mild regurgitation could be seen in the mitral and tricuspid valves (C)

Fig. 4 The cardiac magnetic resonance of the proband II: 1. In the end-diastolic images of cine True-FISP sequence, the short axis view of middle segment (A), coronal view of the left ventricular outflow tract (B), and three-chamber view of the heart (C) showed that myocardial thickening of the subendocardial, basal and middle segment, anterior and anterior-lateral wall of LV. The cardiac trabeculae increased and disordered, showing a reticular/palisade shape (yellow arrow). The maximum thickness ratio of the noncompacted layer to compacted layer (N/C = D2/D1) was between 2.25 and 2.67 in different sections. Deep recess was found among the trabeculae, and the communication existed between trabecular recess and the left ventricular cavity. The interventricular septum was thickened (green arrow) about 18 mm, and the inferior wall of LV became thinner (red arrow). The short-axis view in the middle segment (D) of the T2W-TIRM sequence showed thickening of the anterior and anterior-lateral wall of LV, increased signal intensity in the subendocardial region due to slow blood flow in trabecular recess (yellow arrow), localized thinning of the lateral-inferior wall (red arrow), and general thickening of the ventricular septum (green arrow). The short axis (E) and four-chamber (G, H) views of the first-pass enhancement sequence showed that the early enhancement signal of trabecular recess in the anterior and anterior-lateral wall of LV was consistent with that of the heart cavity (yellow arrow), indicating that there were flowing blood component in it. The short axis (F) and four-chamber (I) views of PSIR-LGE showed extensive abnormal enhancement in the lateral wall of LV (yellow arrow) and abnormal enhancement in the interventricular septum (green arrow). T1W showed no abnormal fat depositing signal in left and right ventricles (blue arrow). Yellow arrow: thickened lateral-anterior wall. Red arrow: thinned lateral wall. Green arrow: thickened interventricular septum. Blue Arrow: normal right ventricular wall

I: 1 (father of II: 1) suffered from hypertension and stroke. He was persistently laid in bed for three years and subsequently died at the age of 67 years. I: 2 (mother of II: 1) died of SCD induced by acute myocardial infarction on the way to the hospital at 73 years old. We could not receive clinical information and blood samples of I: 1 and I: 2. The echocardiograms of II: 2 and II: 3 were normal. No characteristic change related to CMs was observed in the ECGs of II: 2 and II: 3 (Fig. 2G–H).

Genetic screening

We conducted genetic screening for the proband (II: 1) by target capture sequencing, and the rest of the family members were subjected to Sanger sequencing. The genetic screening revealed that the proband (II: 1) carried 10 exonic variants (Table 2), including two variants of DSC2 p.K47Rfs*2 (NM_004949: EX2/CDS2: c.140_147delAACTTGTT) and DSC2 p.I520T (NM_004949: EX11/CDS11: c.1559T>C), which were located in chromosome 18. The local and 1000 Genomes Project database frequency of DSC2 p.K47Rfs*2 and p.I520T was less than 0.001. DSC2 p.K47Rfs*2 was not detected in gnomAD exomes combined population. Desmocollin2 encoded by the DSC2 gene was an important component for desmosome assembly. Abnormal desmocollin2 caused the dysfunction of cell–cell adhesions and intercellular gap junctions, failing to hold together the cardiomyocytes, fibrofatty myocardial replacement, cardiac conduction delay, mechanically ventricular dysfunction and arrhythmias [23]. According to the protein reference sequence, DSC2 p.K47Rfs*2 converted the 47th amino acid (AA) from lysine to arginine and led to a premature termination codon at the 48th AA, which was therefore considered as frameshift and truncated mutation. This phenomenon caused the interrupting protein synthesis at the cadherin pro domain and loss of protein structure, including extracellular domains 1–4, extracellular anchor, a transmembrane domain, intracellular anchor, intracellular cadherin-like sequence, resulting in truncated protein without normal function (Fig. 1C). Based on the ACMG/AMP guidelines [14], the null variant (e.g., frameshift mutation) in a gene where the loss of function is a known disease mechanism was classified as PVS1, suggesting strong evidence of pathogenicity. Therefore, DSC2 p.K47Rfs*2, as a truncated and loss-of-function mutation, served as PVS1. DSC2 p.I520T (rs561310777) was demonstrated to be benign or likely benign by Clinvar database and the CHEO Genetics Diagnostic Laboratory in Children’s Hospital of Eastern Ontario (https://www.ncbi.nlm.nih.gov/clinvar/variation/155783/). The MAF of DSC2 p.I520T was 0.02% and not fulfilled with the criteria of the vast majority of reported pathogenic variants (MAF < 0.01%). Additionally, according to the analysis of the UCSC Genome Browser, the amino acid site of DSC2 p.I520 is not conserved in several species (Fig. 1D). Based on the genotype of II: 1, II: 2 did not carry heterozygous DSC2 p.K47Rfs*2 or p.I520T, whereas II: 3 with normal electrocardiogram and echocardiography only carried the heterozygous DSC2 p.I520T (Fig. 1A and B), indicating that these two variants were not linked on the same chromosome, but located on the homologous chromosomes, respectively. The variants of CACNA1C, COL5A1, GDF1, HTRA1, MEF2A, TSPYL1, and TTN were classified as benign or likely benign by the Clinvar database and ACMG guideline algorithm. Recently, no study confirmed that ELN variants cause CMs. The variant of ELN p.T248S was predicted to be tolerated/benign by SIFT and MetaSVM algorithms.Table 2 Predisposing analysis of genetic variants suspected to arrhythmia and cardiomyopathies for II: 1

Chr	Gene	Transcript	Zygosity	RS-ID	1000G	Local Fre	GnomAD	SIFT	PolyPhen	MetaSVM	Clinvar	ACMG classification	
chr12	CACNA1C	NM_001129827, c.5753C>T, p.T1918M	Het	rs201777030	0	A	0.0011	0.17 (T)	0.60 (P)	T	B	US	
chr9	COL5A1	NM_000093, c.61C>T, p.P21S	Het	rs548525119	0	A	0.0011	0.43 (T)	0.00 (B)	T	B	B	
chr18	DSC2	NM_004949, c.1559T>C, p. I520T	Het	rs561310777	0	A	0.0002	0.00 (D)	0.47 (P)	T	B	US	
chr18	DSC2	NM_004949, c.140_147delAACTTGTT, p. K47Rfs*2	Het	–	0	A	–	–	–	–	–	LP	
chr7	ELN	NM_000501, c.742A > T, p. T248S	Het	–	0	A	0.000004064	0.35 (T)	0.97 (P)	T	–	US	
chr19	GDF1	NM_001492, c.470_471insGGC	Het	rs571387097	0	A	0.038	–	–	–	B	LB	
chr10	HTRA1	NM_002775, c.59C > T, p.A20V	Het	rs369149111	0	A	0.0207	0.53 (T)	0.00 (B)	T	B	B	
chr15	MEF2A	NM_005587, c.1234_1236delCAG	Het	rs373652230	0	A	0.1518	–	–	–	B	B	
chr6	TSPYL1	NM_003309, c.528_529insGTG	Hom	rs397735194	0	A	–	–	–	–	–	B	
chr2	TTN	NM_001267550, c.36655T>G, p. L12219V	Hom	rs139508281	0	A	0.0954	–	0.00 (U)	T	B	B	
Chr: chromosome. Fre: frequency. Het: heterozygosis. Hom: homozygosis. GnomAD: frequency of existing variant in gnomAD exomes combined population. Local Fre: frequency information about this SNP in sequencing samples of over 200 normal people collected locally. Local frequency: 0–0.01 = A; 0.01–0.05 is B (including 0.01 and 0.05); 0.05–1 is C. P: possibly damaging; T: tolerated; U: unknown. 1000G: 1000 Genomes Project databases (2014version). B: benign. D: deleterious. US: uncertain significance. LB: likely benign. LP: likely pathogenic. –, no report

Literature review of LVNC

We searched the NCBI database for studies with the theme of “left ventricle noncompaction” on June 13, 2021. We summarized the genes and their mutations associated with LVNC, which were predicted as likely pathogenic and pathogenic by ≥ 2 predicting algorithms, familial cosegregation validation, and molecular and/or animal/cell experiments, as shown in Table 3. Results showed that MYH7, MYBPC3, TPM1, TAZ, TTN, and NONO genes were the most common genes causing LVNC. LVNC caused by MYH7 and MYBPC3 mutations often complicated congenital heart diseases (CHD), such as atrial septal defect, ventricular septal defect, Ebstein, tetralogy of Fallot, patent ductus arteriosus, patent foramen ovale, and aortic hypoplasia. Some cases occurred with thromboembolism. Recently, LVNC induced by DES and DSP mutations was common and young-onset with HCM, DCM, ACM, myocarditis and HF, complicating ventricular and atrial tachycardias, and even needed therapy of heart transplantation in some cases. LVNC was associated with FBN1 mutation combined with DCM and Marfan syndrome. LVNC induced by HCN4 and EMD mutations complicated sick sinus syndrome (SSS), AF, atrial standstill, and interventricular block. Additionally, the LVNC induced by EMD mutation was combined with DCM. The LVNC caused by RYR2, KCNQ1, and KCNH2 mutations occurred with catecholamine-sensitive VT, long QT syndrome (LQTs), torsade de pointes, and ventricular fibrillation. In contrast, the LVNC result from SCN5A mutation complicated SSS, AF, LQTs, Wolff–Parkinson–White syndrome, VT, and atrioventricular block. Some genes led to LVNC and caused complex and critical clinical disease syndromes, such as Rubinstein–Taybi syndrome (i.e., ABCC9 gene), Ehlers–Danlos syndrome (i.e., COL3A1 gene), Emery–Dreifuss muscular dystrophy (i.e., EMD gene), Danon disease (i.e., LAMP2 gene), intellectual disability syndrome (i.e., NONO gene), Sotos syndrome (i.e., NSD1 gene), LEOPARD syndrome (i.e., PTPN11 gene), Coffin-Lowry syndrome (i.e., RPS6KA3 gene), Cornelia de Lange syndrome (i.e., SMC1A gene), Barth syndrome (i.e., TAZ gene), and Holt–Oram syndrome (i.e., TBX5 gene). Additionally, ARFGEF2, MIPEP, NONO, SH2B1, and TMEM70 led to LVNC complicating developmental delay. The deletion of one of these genes, including FKBP12, JARID2, NUMB, and PLZND1, induced LVNC by affecting the activity of the Notch signaling pathway in animal models, which had not been discovered in clinical cases until now. For these genes from Table 3, only ACTC1, ACTN2, DTNA, LDB3, MIB1, MYBPC3, MYH7, PRDM16, TNNT2, and TPM1 were reported to be associated with LVNC in the OMIM database (Table 4).Table 3 The detailed mutations and their clinical characteristics associated with left ventricular noncompaction

Gene	Mutation	Sex	Aged	LVNC	HCM	DCM	ACM	RCM	HF	SCD/VF	CTR	MA	Other	FV	FA		
ABCC9	NM_005691, c.3594G>A, p.M1198I, rs199900459	M	32	+	−	−	−	−	−	−	−	−	Rubinstein–Taybi syndrome	−	−	[58]	
ACTC1	NM_005159.4, c.62C>T, p.A21V	M	10 y	+	+	−	−	−	−	+	−	−	Transmural crypts	+	−	[59]	
ACTC1	NM_005159.4, c.301G>A, p.E99K	M	11 y	+	+	−	−	−	−	−	−	−	−	+	+	[60]	
ACTC1	NM_005159.4, c.478G>A, p.E101K	M	15 y	+	+	−	−	−	+	+	+	−	−	+	−	[61-64]	
ACTC1	NM_005159.4, c.659A>C, p.Y220S	M	3 y	+	−	−	−	−	−	−	−	−	VT	−	−	[65]	
ACTC1	NM_005159.4, c.692C>G, p.T231R	M	11 y	+	−	−	−	−	−	−	+	−	−	−	−	[65]	
ACTC1	NM_005159.4, p.I289T	F	9 m	+	−	−	−	+	+	−	+	−	ASD	+	−	[66]	
ACTC1	NM_005159.4, c.886T>C, p.Y296H	−	13 y	+	+	+	−	−	−	−	−	−	−	−	−	[67]	
ACTC1	NM_005159.4, c.986T>C, p.I329T	F	48 y	+	−	−	−	−	−	+	−	−	VF, AF, IVB	+	−	[68]	
ACTC1	NM_005159.4, c.670G>T, p.D224Y	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
ACTC1	NM_005159.4, c.281A>G, p.N94S	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
ACTC1	NM_005159.4, c.623G>A, p.R208H	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
ACTN2	NM_001103.2, c.683T>C, p.M228T	M	30 y	+	+	−	−	−	+	−	−	−	AF, AVB, esophageal atresia, tracheal fistula, ASD	+	−	[69]	
ACTN2	chr1: 236881238:CCT>– NM_001278343, p.L70del	F	9 y	+	+	−	−	−	−	+	−	−		+	−	[9]	
ACTN2	NM_001103.3, c.668T>C, p.L223P	M	15 y	+	+	+	−	−	+	−	−	−	−	+	−	[70]	
ANK2	NM_001148.4, c.11150T>A, p.I3717N	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
ANK2	NM_001148.4, c.9145C>T, p.R3049W	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
ALPK3	NM_020778, c.639G>A, p.W213X	M	34 w	+	+	+	−	−	+	−	−	−	PFO, VSD	+	−	[71]	
ARFGEF2	NM_006420.2, c.5126G>A, p.W1709X	F	10 y	+	−	−	−	−	−	−	−	−	Movement disorder, developmental delay and microcephaly	−	−	[72]	
BAG3	NM_004281.3, c.465_466insGCG, p.A156dup	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
BRAF	chr7:140477829:->A, NM_004333, p.Q493H MYH6:chr14: 23858233:G>A, NM_002471, p.S1337L, rs758922922	M	9 y	+	+	+	−	−	+	−	−	−	AVB, SVT	−	−	[9]	
BMP10	NM_014482.3, c.1219G>A, p.V407I	F	−	+	−	−	−	−	−	−	−	−	−	+	+	[73]	
BMP10	deletion	−	−	+	−	−	−	−	−	−	−	−	−	−	+	[74]	
CACNA2D1	g.81603880_81603881delAA, NM(-), NP(-), p.R652RfsX3 and RANGRF, NM(-), NP(-), p.P155S	F	1 m	+	−	−	−	−	+	+	+	−	Histiocytoid cardiomyopathy, WPW, arrhythmia storms	−	−	[75]	
CASQ2	NM_001232.4, p.H244R	M	53 y	+	−	−	−	−	−	−	−	−	thrombus	+	−	[76]	
CASZ1	NM(-), NP(-), c.2443_2459del, p.V1815PfsX14	M	11 m	+	−	+	−	−	+	−	−	−	−	−	−	[8]	
CDK10	NM_052988.4, c.452T>C, p.L151P. Chromosome 16q24.3 deletion encompassing 9 genes: CDK10, CPNE7, DPEP1, CHMP1A, SPATA33, SPATA2L, VPS9D1, ZNF276,and FANCA	M	3 m	+	−	−	−	−	+	+	−	−	Partial agenesis of the corpus callosum, unilateral multicystic dysplastic kidney, a single central incisor with pyriform aperture stenosis	+	−	[77]	
COL3A1	NM_000090.4, c.2959G>A, p.G987S	M	32 y	+	−	+	−	−	+	−	−	−	Vascular Ehlers-Danlos Syndrome, AF	−	−	[78]	
DES	NM(-), NP(-), p.L69P	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[79, 80]	
DES	NM_001927.3, NP(-), c.336_344del, p.Q113_L115del	M	13 y	+	+	+	−	−	+	+	+	−	VT, AVB	+	+	[81]	
DES	NM(-), NP(-), p.R212Q	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[79, 80]	
DES	NM(-), NP(-), p.A360S	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[79, 80]	
DES	NM(-), NP(-), c. C1360T, p.R454W	F	11 y	+	−	+	−	−	+	−	+	−	Coronary artery dissection, AVB, AFL	+	−	[82]	
DSC2	NM_004949, c.140_147del, p. K47Rfs*2	M	54 y	+	+	−	−	−	+	−	−	−	AF, VT	+	−	This study	
DSC2	NM_024422.3, c.1448A>T, p.N483I	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
DSP	NM(-), NC_000006.11, c.1339C>T	M	37 y	+	−	+	+	−	+	+	−	−	VT, myocarditis	+	−	[83]	
DSP	NM_004415.2, c.3035delA, p.D1012fs	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
DSP	NM(-), NP(-), c.5208delAG, p.G1737fsX1742	M	5 y	+	−	+	−	−	+	+	−	−	Palmoplantar keratoderma	+	−	[84]	
DTNA	NM(-), NP(-), c.146A>G, p.N49S	M	39 y	+	−	+	−	−	+	−	−	−	−	+	+	[85]	
DTNA	NM(-), NP(-), c. 362 C>T, p.P121L	F	2 d	+	−	−	−	−	+	+	−	−	PDA, AF, VSD	+	−	[86-88]	
EMD	NM(-), NP(-), c.226-2A>C	M	16 y	+	−	+	−	−	−	−	−	−	SSS, PFO, AS, Emery-deifuss muscular dystrophy	+	−	[89]	
EMD	NM(-), NP(-), c.1A>G, p.M1V	M	53 y	+	−	+	−	−	+	−	−	−	SSS, AF, AS	+	−	[89]	
EMD	NM(-), NP(-), c.23C>T, p.S8L	M	65 y	+	−	+	−	−	−	−	−	−	AVB, VT	+	−	[89]	
EMD	NM(-), NP(-), c.415delC, p.L39fsX98	M	13 y	+	−	+	−	−	−	−	−	−	SSS, AS	+	−	[89]	
FBN1	NM(-), NP(-), c.1633 C>T	F	14 y	+	−	+	−	−	+	−	−	−	Marfan syndrome	−	−	[90]	
FBN1	NM(-), NP(-), c.3173 G>T	F	20 y	+	−	+	−	−	+	−	−	−	Marfan syndrome	−	−	[90]	
FBN1	NM(-), NP(-), c.6832 C>T	M	2 y	+	−	+	−	−	+	−	−	−	Shprintzen-Goldberg	−	−	[90]	
FKBP12	deletion	−	−	+	−	+	−	−	−	−	−	−	VSD, CHD	−	+	[38, 39]	
FKTN	NM(-), NP(-), c.536G>C, p.R179T	M	26 y	+	−	+	−	−	+	−	−	−	−	−	−	[91]	
FLNC	NM_001458.4, c.1933_1935del, p.645del	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
FLNC	NM(-), NP(-), c.4997T>C, p.I1666T	M	37	+	−	−	−	−	−	−	−	−	AF	−	−	[92]	
GATA4	NM(-), NP(-), c.778 C>T, p.A242V and PTEN: NM(-), NP(-), c.517C>T, p.R173C	M	19 y	+	−	−	−	−	−	−	−	−	−	+	+	[93]	
HADHB	NM(-), NP(-), c.1109+243_1438-703del	−	Fetus	+	+	−	−	−	+	+	−	−	TFP deficiency, lactic acidosis, hypoketotic hypoglycemia, and neonatal death	+	−	[94]	
HCN4	NM_005477.2, c.1123C>T, p.R375C	F	16 y	+	−	−	−	−	−	−	−	−	SSS, left atrial dilatation	+	+	[33, 95]	
HCN4	NM_005477.2, c.1231C>G, p.L411V	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
HCN4	NM(-), NP(-), c.1241C>G, p.A414G	M	74 y	+	−	−	−	−	−	−	−	−	SSS, AF	+	+	[96]	
HCN4	NM_005477.2, c.1403C>T, p.A468V	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
HCN4	NM_005477.2, c.1438G>T, p.G480C	M	−	+	−	−	−	−	−	−	−	−	SSS	+	−	[33]	
HCN4	NM(-), NP(-), c.1441T>C, p.Y481H	F	53	+	−	−	−	−	−	−	−	−	SSS, AF	+	+	[96]	
HCN4	g.73622060 G>A, NM_005477.2, c. 1444G>A, p.G482R	M	23 y	+	−	−	−	−	+	+	−	−	SSS	+	+	[33, 96-98]	
HCN4	NM(-), NP(-), p.R483_V487del	F	47 y	+	−	−	−	−	−	−	−	−	SSS, AF,Thoracic aortic aneurysms	+	−	[99]	
HCN4	NM_005477.2, c.2432G>A, p.G811E	F	6 m	+	−	+	−	−	+	−	−	−	VSD, IVB	+	+	[100]	
HEY2	NM_012259, c.683C>T p.T228M	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
Jarid2	deletion	−	−	+	−	−	−	−	−	−	−	−	VSD	−	+	[101]	
KCNH2	NM_001204798, c.818 C>T, p.T273M	F	22 y	+	−	−	−	−	−	+	−	−	LQTs, Tdp, VT, VF	+	+	[102]	
KCNQ1	NM(-), NP(-), c.817C>T, p.L273F	M	48 y	+	−	−	−	−	−	−	−	−	LQTs, VSD	+	−	[103]	
KCNQ1	NM(-), NP(-), c.1831 G>T, p.D611T	F	5 y	+	−	−	−	−	−	+	−	−	LQTs, VT, VF, epilepsy	+	−	[104]	
LAMP2	NM(-), NP(-), c.64+2T>A	F	23 y	+	−	+	−	−	+	−	−	−	VSD	+	−	[105]	
LAMP2	NM_002294.2, c.987T>G, p.Y329X	M	21 y	+	−	−	−	−	−	−	−	−	Electrical myotonia, Danon disease	+	−	[106]	
LDB3	NM_007078.2, c.608C>T, p.S203L	−	−	+	−	−	−	−	−	−	−	−	Congenital muscular dystrophy	−	−	[33]	
LDB3	NM_007078.2, c.625G>C, p.E209Q	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
LDB3	NM(-), NP(-), c.163G>A, p.V55I	F	14 y	+	−	+	−	−	−	−	−	−	−	−	−	[88]	
LDB3	NM(-), NP(-), c.349G>A, p.D117N	M	33 y	+	+	+	−	−	−	−	−	−	IVB	−	+	[107, 108]	
LDB3	NM(-), NP(-), c.587C>T, p.S196L	M	40 y	+	+	+	−	−	+	+	−	−	−	+	+	[88, 109-111]	
LDB3	NM(-), NP(-), c.1876G>A, p.D626N	M	13 y	+	−	−	−	−	−	+	−	−	WPW	+	−	[86, 88]	
LMNA	NM(-), NP(-), c.1608+5G>C and LDB3: NM(-), NP(-), p.D117N	M	30 y	+	+	+	−	−	+	+	−	−	Limb girdle muscular dystrophy, VT, AF, CAVB	+	−	[76]	
LMNA	NM(-), NP(-), c.1968+26A>G and TAZ: NM(-), NP(-), p.F128S	M	57 y	+	−	−	−	−	−	+	−	−	−	+	−	[76]	
LMNA	NM_170707.2, c.738delG, p.Q246fs	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
LMNA	NC_000001, c. T1334A, p.V445E	M	23 y	+	−	−	−	−	−	+	−	−	VT/VF	+	+	[112]	
LMNA	NM(-), NP(-), c.1930C>T, p.R644C	F	2 y	+	−	+	−	−	−	−	−	−	VSD, dysmorphism, multicystic and dysplastic kidney	+	−	[113, 114]	
MEF2A	NM(-), NP(-), p.R17X	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[80]	
MIB1	NM(-), NP(-), c.1587C>T, p.R530X	−	−	+	−	−	−	−	−	−	−	−	−	+	+	[115]	
MIB1	NM(-), NP(-), c.2827G>T, p.V943F	−	−	+	−	−	−	−	−	−	+		−	+	+	[115]	
MIB2	NM_080875, c.2225T>G, p.V742G	F/M	−	+	−	−	−	−	−	−	−	−	Menetrier-like gastropathy	+	+	[116]	
MIB2	NM_080875, c.2950G>C, p.V984L	F	−	+	−		−	−	−	−	−	−	Menetrier-like gastropathy	+	+	[116]	
MIPEP	NM_005932, c.1745T>G, p.L582R and c.212T>A, p.L71Q	M	5.5 m	+	−	−	−	−	−	+	−	−	WPW, seizures, hypotonia, developmental delay, respiratory chain disorder	+	+	[117]	
MIPEP	NM_005932, c.916C>T, p.L306F and c.1804G>T, p.E602X	F	11 m	+	−	+	−	−	−	+	+	+	Developmental delay, metabolic myopathy, diffuse neuronal loss, eosinophilic esophagitis	+	+	[117]	
MMACHC	NM(-), NP(-), c.271dupA	F	35 w	+	−	−	−	−	−	+	−	−	Intracellular vitamin B12 disorder	−	−	[118]	
MYBPC3	NM(-), NP(-), c.68G>A, p.G5R	M	20 y	+	−	−	−	−	−	−	−	−	−	−	−	[119]	
MYBPC3	NM(-), NP(-), p.G148R	M	30 y	+	+	+	−	−	+	+	−	−	TOF, mesenteric thrombosis, myelofibrosis	+	−	[76]	
MYBPC3	NM_000256.3, c.532G>A, p.V178M	−	−	+	+	−	−	−	−	−	−	−	−	−	−	[33]	
MYBPC3	NM(-), NP(-), p.A216T and ACTC1: NM(-), NP(-), 22C>T	M	50 y	+	−	−	−	−	+	−	−	−	VT	+	−	[76]	
MYBPC3	NM(-), NP(-), c.1523GA, p.G490R	M	32 y	+	−	−	−	−	−	−	−	−	−	+	−	[119]	
MYBPC3	NM_000256.3, c.1504C>T, p.R502W	F	19 y	+	+	−	−	−	−	−	−	−	−	+	−	[33, 120]	
MYBPC3	NM(-), NP(-), p.R502Q and p.R943X	M	−	+	+	−	−	−	−	+	+	−	−	+	−	[121]	
MYBPC3	NM(-), NP(-), c.2373dup, p.W792fs	F	7 w	+	+	+	−	−	−	+	−	−	PFO and mitral valve insufficiency	+	−	[122]	
MYBPC3	NM(-), NP(-), c.2460C>T, p.R820W	F	43 y	+	+	+	−	−	−	+	−	−	AF	+	−	[123]	
MYBPC3	NM_000256, NP_000247, c.2572A>C, p.S858R	F	2 m	+	−	+	−	−	+	−	+	+	−	+	+	[124]	
MYBPC3	NM(-), NP(-), c.2673C>T, p.P873L	M	37	+	−	−	−	−	+	−	−	−	Pulmonary hypertension	−	−	[119]	
MYBPC3	NM(-), NP(-), c.2827C>T, p.R943X	M	5 w	+	+	+	−	−	+	+	−	−	ASD	+	−	[122]	
MYBPC3	NM(-), NP(-), c.2919-2920delCT, p.P955RfsX95	F	28	+	−	−	−	−	−	−	−	−	VT	−	−	[119]	
MYBPC3	NM(-), NP(-), c.2864_2865del, p.P955fs and c.1513_1515del, p.K505del	F	5 m	+	+	+	−	−	+	+	−	−	−	+	−	[125]	
MYBPC3	NM(-), NP(-), c.2909G>A, p.R970Q	M	−	+	−	−	−	−	−	+	−	−	−	+	−	[65]	
MYBPC3	NM(-), NP(-), c.3408C>A, p.Y1136X and c.2373dupG	M	36 w	+	+	−	−	−	+	−	−	−	−	+	−	[126]	
MYBPC3	NM(-), NP(-), 377delA, p.Q1259fs and c.3599T>C, p.L1200P	M	11 d	+	+	−	−	−	+	+	+	+	−	+	−	[127]	
MLYCD	c.393_400del8	F	10 m	+	−	+	−	−	−	−	−	−	Malonyl coenzyme A decarboxylase deficiency	−	−	[128]	
MYH6	NM_002471.3, c.50G>T, p.R17L	−	−	+	−	−	−	−	−	−	−	−	CHD	−	−	[33]	
MYH6	NM_002471.3, c.1793dupA, p.N598fs	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
MYH6	NM_002471.3, c.4828C>T, p.R1610C	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
MYH7	NM_000257, c.130C>T, p.Q44X and c.5029C>T, p.R1677C	M	32 y	+	−	−	−	−	+	−	−	−	Ebstein	+	−	[124]	
MYH7	NM_000257, c.379C>A, p.P127T	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
MYH7	NM_000257, c.464_466del, p.delF155	M	8 y	+	−	−	−	−	−	−	−	−	ASD, Ebstein	−	−	[68]	
MYH7	g.23901862T>G, NM_000257, p.Q163P	−	−	+	+	−	−	−	−	−	−	−	−	+	−	[129]	
MYH7	NM_000257, c.801_803delGAC, p.D239del	M	65 y	+	−	−	−	−	+	−	−	−	AVB	−	−	[62]	
MYH7	NM_000257, c.814G>A, p.R243H	M	25 y	+	−	−	−	−	+	−	+	−	AF	+	−	[62]	
MYH7	NM_000257, c.745C>G, p.R249G	F	35 y	+	−	−	−	−	+	−	−	−	IVB	+	−	[68]	
MYH7	NM_000257, c.840T>C, p.F252L	M	58 y	+	−	−	−	−	+	+	−	−	NSVT	−	−	[62]	
MYH7	NM_000257, p.R281T	−	−	+	−	−	−	−	−	−	−	−	Ebstein, CHD	+	−	[130]	
MYH7	NM_000257, p.Y283D	F	49 y	+	−	−	−	−	−	−	−	−	Ebstein, ASD, VSD, CHD	+	−	[130, 131]	
MYH7	NM_000257, c.847T>C, p.Y283H	M	−	+	−	−	−	−	−	−	−	−	−	+	−	[65]	
MYH7	NM_000257, p.L301Q	M	12 y	+	−	−	−	−	+	−	−	−	Ebstein	+	−	[76, 130]	
MYH7	NM_000257, p.Y350D	−	−	+	−	−	−	−	−	−	−	−	Ebstein	−	−	[130]	
MYH7	NM_000257, p.E1350del	F	32 y	+	−	−	−	−	+	−	−	−	Aortic insufficiency	+	−	[76]	
MYH7	NM_000257, p.Y350N	F	26 y	+	−	−	−	−	−	−	−	−	Ebstein	−	−	[131]	
MYH7	NM_000257, c.1085T>G, p.M362R	F	infant	+	−	−	−	−	−	−	−	−	Ebstein, ASD, VSD	+	−	[132, 133]	
MYH7	NM_000257, c.1106G>A, p.R369Q	F	8 m	+	−	+	−	−	+	−	−	−	−	+	−	[127, 68]	
MYH7	NM_000257, p.L390P	M	59 y	+	−	−	−	−	−	−	−	−	Ebstein, PFO, AF, CHD	−	−	[131, 130]	
MYH7	NM_000257, c.1207C>T, p.R403W and c.1000–1G>A	M	14 y	+	+	−	−	−	−	+	−	−	VF	+	−	[124]	
MYH7	NM_000257, p.K1459N	−	−	+	−	−	−	−	−	−	−	−	Ebstein	−	−	[130]	
MYH7	g:23897795G>C, NM_000257, c. 1492C>G, p.Q498E	M	19 y	+	−	−	−	−	−	−	−	−	−	+	−	[134]	
MYH7	NM_000257, c.1678T>G, p.M531R	F	14 y	+	−	+	−	−	+	+	−	−	−	+	+	[135, 136]	
MYH7	NM_000257, p.D545N and p.D955N	M	35 y	+	−	−	−	−	+	−	−	−	Thrombus	+	−	[76]	
MYH7	g.23896462G>A, NM_000257, p.S648L	−	−	+	−	+	−	−	−	−	−	−	−	+	−	[129]	
MYH7	NM_000257, p.L658V	M	61 y	+	+	−	−	−	−	−	−	−	−	−	−	[76]	
MYH7	NM_000257, c.A2010_G2031del, p.R671_E677del	M	11 y	+	−	−	−	−	+	−			VSD	−	−	[137]	
MYH7	g.23895236T>C, NM_000257, p.E700G	−	−	+	+	−	−	−	−	−	−	−	−	+	−	[129]	
MYH7	NM_000257, c.2155C>T, p.R719W	M	29 y	+	+	−	−	−	+	+	−	−	−	+	−	[138]	
MYH7	NM_000257, c.2419C>G, p.R807G	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
MYH7	NM_000257, p.I818N	M	21 y	+	+	−	−	−	−	+	−	−	−	+	−	[76]	
MYH7	NG_016984.1, p.R890C	F	1 m	+	−	+	−	−	+	−	−	−	PDA, PFO	+	−	[139]	
MYH7	NM_000257, p.C905R	M	30 y	+	−	+	−	−	−	−	−	−	Cardiac valvular disease	+	−	[140]	
MYH7	NM_000257, c.2785G>A, p.E929K	M	42 y	+	−	+	−	−	+	+	−	−	VT, IVB	+	−	[68]	
MYH7	NM_000257, c.3586C>T, p.H1196Y	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
MYH7	NM_000257, p.1220delE	M	35 y	+	−	−	−	−	−	−	−	−	Ebstein	−	−	[130, 131]	
MYH7	NM_000257, c.3830G>C, p.R1277P	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
MYH7	NM_000257, c.3748C>T, R1250W	M	55 y	+	+	+	−	−	+	−	+	−	−	+	−	[127]	
MYH7	NM_000257, p.R723G and p.S1335L	M	22 y	+	+	−	−	−	−	+	+	−	−	+	−	[121]	
MYH7	NM_000257, c.4161C>T, p.R1359C	M	29 y	+	−	−	−	−	+	−	−	−	AF	−	−	[62]	
MYH7	NM_000257, c.4090G>C, p.A1364P	M	−	+	−	−	−	−	−	−	−	−	−	+	−	[65]	
MYH7	NM_000257, p.K1459N	F	58 y	+	−	−	−	−	−	−	−	−	Ebstein, SVT	−	−	[131]	
MYH7	NM_000257, p.Y1488C	M	41 y	+	−	−	−	−	+	−	−	−	−	+	−	[76]	
MYH7	NM_000257, c.4588C>T, p.R1530X	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
MYH7	NM_000257, p.E1573K	F	33 y	+	−	−	−	−	−	−	−	−	Ebstein, VSD	+	−	[130, 131]	
MYH7	NM_000257, c.5030G>A, p.R1677H	M	−	+	−	−	−	−	−	−	−	−	−	+	−	[65]	
MYH7	NM_000257, c.5382G>A, p.A1766T	M	20 y	+	−	−	−	−	−	−	−	−	−	−	−	[62]	
MYH7	NM_000257, c.5401G>A, p.E1801K	M	25 y	+	−	−	−	−	−	−	−	−	AVB, neurological deficits, Laing distal myopathy	+	−	[141]	
MYH7	NM_000257, c.5566G>A, p.E1856K	F	37 y	+	−	+	−	−	+	+	−	−	VF, distal myopathy	+	−	[142]	
MYH7	NM_000257, p.N1918K	M	5 y	+	−	−	−	−	−	−	−	−	Ebstein, aorta coarctation	+	−	[131, 130, 76]	
MYH7	NM_000257, p.R1925G	F	50 y	+	−	−	−	−	+	+	−	−	−	+	−	[76]	
MYH7	NM_000257, c.8183G>C	M	14 y	+	−	−	−	−	−	−	−	−	−	+	−	[62]	
MYLK2	NM_033118.3, c.1754T>A, p.I585N	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
MYLK2	NM_033118.3, c.1658G>A, p.R553H	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
MYOT	NM_000257, c.179C>T	M	72 y	+	−	−	−	−	−	−	−	−	Myopathy	−	−	[143]	
MYPN	NM_032578.2, c.3457G>A, p.G1153R	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
NEBL	NM_006393.2, c.2747C>T, p.P916L	M	37 y	+	−	+	−	−	+	−	−	−	VT	−	−	[144]	
NKX2.5	NM(-), NP(-), p.K183N	F	30 y	+	−	+	−	−	+	+	−	−	ASD, VF	+	−	[145]	
NKX2.5	NM(-),NP(-), c.512InsGC, p.170X	M	−	+	−	−	−	−	−	+	−	−	ASD, conduction defects,	+	+	[146]	
NKX2.5	NM_004387.3, c.604C>G, p.L202V	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
NEXN	NM_144573.3, c.2012T>C, p.I671T	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
NEXN	NM_144573.3, c.1396A>C, p.K466Q	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
NNT	NM_012343, c.638_639insT, p.R213fs	−	−	+	−	+	−	−	+	−	+	+	−	+	+	[129]	
NONO	NM_001145408.1, c.154+9A>G. MYH6: NM_002471.3, c.718G>A, p.D240N	−	Fetus	+	−	−	−	−	−	−	−	−	Mitral valve dysplasia, and aorta hypoplasia	+	+	[147]	
NONO	NM_001145408, c.1171+1G>T	M	17 y	+	−	−	−	−	−	−	−	−	Intellectual disability syndrome	−	−	[148]	
NONO	NM_001145408, c.1171+1G>A	M	4 y	+	+	−	−	−	−	−	−	−	Intellectual disability syndrome	−	−	[149, 150]	
NONO	NM_001145408.1, the first three coding exons and 19 kb of sequence upstream of the transcriptional start site	M	1 m	+	−	−	−	−	+	+	+	−	PFO, Ebstein, developmental delay, encephalopathy, seizures and dysautonomia, cerebellum dysplasia	+	−	[151]	
NONO	NM_001145408, c.154+5_154+6delGT, p.N52SfsX6	M	2 y	+	−	+	−	−	+	−	−	−	Ebstein, PFO, intellectual disability syndrome	+	−	[152]	
NONO	NM_001145408.1, c.246_249del, p.P83TfsX7	M	fetus	+	−	−	−	−	−	−	−	−	Ebstein, PS, VSD, VSD, PLSVA, cardiovascular hypoplasia or transposition	+	−	[153]	
NONO	NM_001145408, c.550C>T, p.R184X	M	2 y	+	−	+	−	−	−	−	−	−	ASD, VSD, PDA, aortic dilatation, intellectual disability syndrome	−	−	[149, 150]	
NONO	NM_001145408, c.1093C>T, p.R365X	M	10 y	+	+	+	−	−	+	−	−	−	RVH, ASD, VSD, PDA, Intellectual disability syndrome	−	−	[151]	
NONO	NM_001145408, c.1394dupC, p.N466KfsX13	M	5 y	+	−	−	−	−	−	−	−	−	ASD, VSD, PDA, intellectual disability syndrome	−	−	[151]	
NONO	NM_001145408.1, c.471del, p.Q157HfsX18	M	fetus	+	−	−	−	−	−	+	−	−	Ebstein, PS, ASD, VSD, aortic arch variation, endocardial fibroelastosis, PFO, corpus callosum hypoplasia			[153]	
NRG1	NM(-), NP(-), c.661G>A, p.W143X	M	−	+	−	−	−	−	−	−	−	−	−	+	+	[73]	
NSD1	NM(-), NP(-), c.6218_6219insG	M	11 y	+	−	+	−	−	−	+	−	−	Sotos syndrome	−	−	[1]	
NSD1	NM(-), NP(-), c.2604_2605dupTT	F	6 y	+	+	−	−	−	−	−	−	−	Sotos syndrome	−	−	[1]	
NUMB	deletion	−	−	+	−	−	−	−	−	−	−	−	VSD	−	+	[154]	
OBSCN	g.228552766_228552767delinsG, NM(-), NP(-), p.T7266RfsX53	M	56 y	+	−	−	−	−	−	−	−	−	−	−	−	[155]	
OBSCN	g.228559442delC, NM(-), NP(-), p.S7947PfsX82, rs71180793	F	30 y	+	−	−	−	−	−	−	−	−	−	−	−	[155]	
OBSCN	g.228562285G>C, NM(-), NP(-), c.25367-1G>C, rs55883237	M	39 y	+	−	−	−	−	−	−	−	−	−	−	−	[155]	
PDLIM3	NM_014476.4, c.742C>T, p.R248C	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
PKP2	deletion	F	12 d	+	−	−	−	−	+	+	−	−	−	+	−	[50]	
PKP2	NM_004572.3, c.2018G>A, p.G673D	−	−	+	−	−	+	−	−	−	−	−	−	−	−	[33]	
PLEKHM2	NM(-), NP(-), c.2156_2157delAG, p.K645AfsX12	M	7 y	+	−	+	−	−	+	+	+	−	VT	+	+	[156]	
Plxnd1	deletion	−	−	+	−	−	−	−	−	−	−	−	VSD, aortic arch anomalies, persistent truncus arteriosus	−	+	[42]	
PLN	NM(-), NP(-), p.R14del	F	48 y	+	−	−	−	−	−	−	−	−	MVT, thrombus	+	−	[76]	
PRDM16	NM_022114.3, c.1047dupC, p.S350fsX48	M	4 m	+	−	+	−	−	−	−	−	−	−	+	−	[157]	
PRDM16	g.3322083C>T, NC_000001.10, c.1057C>T, p.Q353X	−	31 w fetus	+	−	+	−	−	−	−	−	−	−	+	−	[158]	
PTPN11	NM(-), NP(-), p.W279C	M	40 y	+	+	−	−	−	−	−	−	−	AF, LEOPARD syndrome	−	−	[159]	
RBM20	NM_001134363, c.1901 G>T, p.R634L	F	39 y	+	−	−	−	−	−	+	+	−	TOF	+	+	[34]	
RBM20	NM_001134363, c.1907G>A, p.R636H	F	11 y	+	−	+	−	−	+	−	−	−	−	+	−	[33, 160]	
RBM20	NM_001134363, c.1909A>G, p.S637G	M	13 y	+	−	+	−	−	+	−	−	−	−	+	−	[160]	
Rac1	deletion	−	−	+	−	−	−	−	−	−	−	−	VSD, CHD	−	+	[161]	
RPS6KA3	NM(-), NP(-), c.1000-2A>G	M	1 y	+	−	+	−	+	+	+	−	−	Coffin–Lowry syndrome	+	−	[162]	
RYR2	deletion	F	20 y	+	−	+	−	−	−	+	−	−	AF, VF	+	−	[163-165]	
RYR2	NM(-), NP(-), c.506G>A, p.R169Q	F	5 y	+	−	−	−	−	−	+	−	−	CPVT, VF	+	+	[30]	
RYR2	NM_001035.2, c.169-?_c.273+?del	M	−	+	−	−	−	−	−	−	−	−	−	+	−	[33]	
RYR2	NM_001035.2, c.878A>C, p.Q293P	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
RYR2	NM_001035.2, c.6180G>T, p.Q2060H	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
RYR2	NM_001035.2, c.13936G>C, p.D4646H	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
RYR2	NM(-), NP(-), p.I4855M	F	10 y	+	−	−	−	−	−	+	−	−	CPVT, ASD	+	+	[166]	
SCN5A	NM_198056.1, c.1141-3C>A	M	13 y	+	−	−	−	−	+	−	−	−	PVC, WPW	+	−	[167]	
SCN5A	NM_198056.1, c.87G>A, rs6599230	M	43 y	+	−	−	−	−	−	−	−	−	PVC, LQTs	+	−	[167]	
SCN5A	NM_198056.1, c.453C>T	F	1 w	+	−	−	−	−	+	−	−	−	PVC	+	−	[167]	
SCN5A	NM_198056.1, c.1673A>G, p.H558R, rs1805124	M	13 y	+	−	−	−	−	+	−	−	−	PVC, WPW	+	−	[167]	
SCN5A	NM_198056.1, c.3269C>T, p.P1090L, rs1805125	M	4 y	+	−	−	−	−	+	−	−	−	AF, SSS, PVC	+	−	[167]	
SCN5A	NM_198056.1, c.3996G>A	M	0 y	+	−	−	−	−	+	−	−	−	AVB	−	−	[167]	
SCN5A	NM_198056.1, c.5457T>C, rs1805126	F	5 y	+	−	−	−	−	+	−	−	−	PSVT, VT, AVB, LQTs, SSS, AF, WPW	+	−	[167]	
SDHD	NM(-), NP(-), c.275A>G, p.D92G	M	neonate	+	+	−	−	−	−	+	−	−	Mitochondrial complex II deficiency	−	−	[168]	
SH2B1	Deletion	M	18 d	+	−	−	−	−	−	−	−	−	Aorta stenosis, ASD, developmental delay	+	−	[169]	
SLC39A8	Deletion	−	−	+	−	−	−	−	−	−	−	−	−	−	+	[170]	
SMC1A	NM(-), NP(-), c.1636_1638delATT	F	21 m	+	+	−	−	−	−	−	−	−	Microform Cleft Lip, poor Vision, Cornelia de Lange Syndrome	+	−	[171]	
STRA6	NM_022369.4, c.113+3_113+4del	−	Fetus (22 w)	+	−	−	−	−	−	−	−	−	Syndromic microphthalmia, interrupted aortic arch type A	+	−	[172]	
TAZ	NM_000116.3, p.R94H	M	12 h	+	−	−	−	−	+	+	−	−	−	+	−	[173]	
TAZ	NM_000116.3, intron1+9G>C	M	4 m	+	−	+	−	−	+	+	−	−	Barth syndrome	+	−	[174]	
TAZ	NM_000116.3, c.IVS8-1G>C	M	3 m	+	+	+	−	−	+	+	−	−	−	+	−	[86] [88]	
TAZ	NM_000116.3, IVS10+2T>A	M	8 m	+	−	−	−	−	+	+	−	−	Barth syndrome	+	−	[87, 110]	
TAZ	NM_000116.3, c.109+1G>C	M	4 m	+	−	+	−	−	+	+	−	−	Barth syndrome	+	−	[175]	
TAZ	NM_000116.3, c.777+2T>A	M	infant	+	−	+	−	−	+	+	−	−	Barth syndrome	−	−	[176]	
TAZ	NM_000116.3, c.134_136delinsCC, p.H45PfsX38	M	1.0	+	−	−	−	−	+	+	−	−	Barth syndrome	+	−	[177]	
TAZ	NM_000116.3, 158InsC, p.L53Pfs80X	M	19 y	+	−	−	−	−	−	−	−	−	Barth syndrome	−	−	[88]	
TAZ	chrX:153641550:T>C, NM_000116, p.L82P	M	1 m	+	−	+	−	−	+	+	−	−	VT, VF	−	−	[9]	
TAZ	NM_000116.3, p.C118R	−	5 m	+	−	−	−	−	+	+	−	−	−	−	−	[178]	
TAZ	NM_000116.3, p.C118R and p.T352C	M	5 m	+	−	+	−	−	+	−	−	−	Barth syndrome			[87, 110]	
TAZ	NM_000116.3, c.367C>T, p.R123X	M	20 y	+	−	−	−	−	−	+	−	−	Barth syndrome	+	−	[177]	
TAZ	NM_000116.3, c.527A>G, p.H176R	M	3.0 y	+	−	−	−	−	+	+	−	−	Barth syndrome	+	−	[177]	
TAZ	NM_000116.3, c.583G>T, p.G195X	M	45 y	+	−	+	−	−	+	−	+	−	AF, ASD, barth syndrome	+	−	[179]	
TAZ	NM_000116.3, p.G197R	−	0 d	+	−	−	−	−	+	+	−	−	−	−	−	[178]	
TAZ	NM_000116.3, c.646G>A, p.G216R	M	14 m	+	−	−	−	−	+	−	−	−	Barth syndrome	+	+	[180]	
TAZ	chrX:153648583:A>insAA, NM_000116, p.Y227_F228delinsX	M	6 m	+	+	+	−	−	+	+	−	−	−	−	−	[9]	
TAZ	NM_000116.3, c.710_711delTG, p.V237AfsX73	M	6.5 y	+	−	−	−	−	−	+	−	−	Barth syndrome	+	−	[177]	
TAZ	chrX: 153649305:G>-, NM_000116, p.A281QfsX58	M	1 y	+	+	+	−	−	−	+	−	−	−	−	−	[9]	
TBX5	NM_000192.3, c.510+5G>T	F	34 y	+	−	−	−	−	−	−	−	−	SSS, AF, ASD, Holt-Oram syndrome	+	−	[181]	
TBX5	NM_000192.3, p.S36Tfs*25	F	49 y	+	−	+	−	−	−	−	−	−	SSS, Holt-Oram syndrome	+	−	[181]	
TBX5	NM(-), NP(-), c.791G>A, p.R264K	M/F	3 m	+	−	+	−	−	+	+	−	−	Embolism, VSD	+	+	[182]	
TBX20	NM(-), NP(-), c.785C>T, p.T262M	F	−	+	−	−	−	−	−	−	−	−	−	+	+	[183]	
TBX20	NM(-), NP(-), c. 951C>A, p.Y317X	M/F	−	+	−	+	−	−	−	−	+	−	−	+	+	[183]	
TMEM43	NM_024334.2, c.317A>G, p.Y106C	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
TMEM70	NM_017866.5, c.141delG, p.P48Rfs*2, and c.316+1G>A	M	36 w	+	+	−	−	−	−	−	−	−	Developmental delay, undescended testicle	+	+	[184]	
TNNC1	NM(-), NP(-), c.243G>C, p.M81I	F	5 m	+	−	−	−	−	−	−	−	−	−	+	−	[65]	
TNNC1	NM(-), NP(-), c.281A>C, p.E94A	F	4 m	+	−	−	−	−	+	−	+	−	−	−	−	[65]	
TNNC1	NM(-), NP(-), c.304C>T, p.R102C	F	12 y	+	−	−	−	−	−	−	+	−	−	+	−	[65]	
TNNI3	NM_000363.4, c.575C>A, p.R192H	F	13 y	+	+	−	−	−	−	+			−	−	−	[185]	
TNNT2	NM_001001430.1, c.?GAG>AAG, p.E96K	F	5 m	+	−	−	−	−	+	+	+	−	−	+	−	[186]	
TNNT2	NM_000364.3, c.305G>A, p.R102Q	F	44 y	+	+	−	−	−	−	−	−	−	AF, IVB	+	−	[68]	
TNNT2	NM(-), NP(-), p.D117N	F	45 y	+	+	−	−	−	−	−	−	−	SVT	+	−	[76]	
TNNT2	NM_001001431, c.450C>T, p.R131W	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[62, 187]	
TNNT2	NM(-), NP(-), p.K210del	M	14 y	+	−	+	−	−	+	−	+	−	−	+	−	[121]	
TPM1	NM_00101805.1, c.41A>G, p.D14G	F	20 d	+	−	−	−	−	+	+	−	−	−	−	−	[65]	
TPM1	NM(-), NP(-), c.109A>G, p.K37E	F	8 y	+	−	−	−	−	−	+	−	−	VF, SCD	+	−	[65, 188]	
TPM1	NM_001018007, c.377C>G, p.L113V	F	22 w	+	−	−	−	−	+	+	+	+	Mitral valve insufficiency, pulmonary hypertension	+	−	[189]	
TPM1	NM 001018005.1, c.475G>A, p.D159A	F	2 y	+	−	−	−	−	+	+	+	−	Ebstein	−	−	[190]	
TPM1	NM_00101805.1, NP_001018005.1, c.533G>A, p.R178H	F	13 d	+	−	−	−	−	+	−	+	−	−	−	+	[65]	
TPM1	NM(-), NP(-), c.765G>A, p.E192K	M	55 y	+	−	−	−	−	−	−	−	−	−	−	−	[119]	
TPM1	NM_001018020.1, c.725C>T, p.A242V	M	45 y	+	−	+	−	−	−	+	−	−	VT, AF, IVB	+	−	[68]	
TPM1	NM(-), NP(-), c.933A>G, p.K248E	M	63 y	+	−	−	−	−	+	−	−	−	−	+	−	[119]	
TPM1	g.23857430C>C, NM(-), NP(-), p.D275H	−	−	+	−	+	−	−	−	−	−	−	−	+	−	[129]	
TTN	NM(-), NP(-), c.533C>A, p.A178D	M	20 y	+	+	+	−	−	+	+	−	−	−	+	+	[191]	
TTN	NM(-), NP(-), c.8858_8859del, p.F2953fs	M	17 y	+	−	−	−	−	+	−	−	−	−	+	−	[34]	
TTN	NM_001256850.1, c.43360C>T, p.R14454X	−	−	+	−	−	−	−	−	−	−	−	CHD	−		[33]	
TTN	NM_001256850.1, c.44248C>T, p.R14750X	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
TTN	NM_001256850.1, c.53947C>T, p.R17983X	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
TTN	NM(-), NP(-), c. 54668G>A, p.G18223D	F	30 y	+	−	−	−	−	−	−	−	−	Embolism	+	−	[34]	
TTN	NM_001256850.1, c.61961G>A, p.W20654X	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
TTN	NM_001256850.1, c.64100_64101insTTGA, p.D21368X	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
TTN	NM_001256850.1, c.80845C>T, p.R26949X	−	−	+	−	−	−	−	−	−	−	−	CHD	−	−	[33]	
TTN	NM(-), NP(-), c.81307_81310del, p.I27103fs	M	16 y	+	−	−	−	−	+	+	+	−	AF, VT	+	−	[34]	
TTN	NM_001256850.1, c.82724delA, p.N27575fs	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
TTN	NM(-), NP(-), c.83889_83890del, p.Y27963fs	M	52 y	+	−	−	−	−	+	−	+	−	AF, VT	+	−	[34]	
TTN	chr2: 179425207: GGAACTGTAAATG>-, NM_001267550, p.28547QfsX12, rs762286447	M	1 y	+	−	+	−	−	+	−	−	−	AVB, ASD	+	−	[9]	
TTN	NM_001256850.1, c.93376delA, p.R31126fs	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
TTN	NM_001256850.1, c.98039_98040insTCAA, p.N32680fs	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[33]	
TTN	NM(-), NP(-), c. 9388+1G>C, p.E2989EfsX4 and c. 102439T>C, p.W34072R	F	38 y	+	−	+	−	−	+	−	+	−	VSD, arthrogryposis multiplex congenital	+	−	[192]	
YWHAE	NM(-), NP(-), c.-458G>T	M	2 w	+	−	−	−	−	−	+	−	−	Hypoplasia of the corpus callosum	+	+	[193]	
Mitochondrial DNA																	
Met31	m. 3397A>G	−	−	+	−	−	−	−	−	−	−	−	−	−	−	[194]	
Met31	m. 3398T>C	M	35 y	+	−	−	−	−	−	−	−	−	−	−	−	[194]	
ND1	m.3308T>C	F	6 y	+	−	+	−	−	−	−	−	−	Ebstein	+	+	[195, 196]	
M: male. F: female. y: years. w: weeks. m: months. d: days. LVNC: left ventricular noncompaction. HCM: hypertrophic cardiomyopathy. DCM: dilated cardiomyopathy. ACM: arrhythmogenic cardiomyopathy. RCM: restricted cardiomyopathy. HF: heart failure. SCD: sudden cardiac death. FV: family verification. FA: functional analysis. CTR: cardiac transplantation. MA: mechanical assist. fs: frame-shift mutation. X: truncated mutation. VT: ventricular tachycardia. VF: ventricular fibrillation. MVT: ventricular tachycardia needed resuscitation. AVB: atria-ventricular block. AF: atrial fibrillation. AS: atrial standstill. IVB: intra-ventricular block. ASD: atrial septal defect. CHD: congenital heart disease. VSD: ventricular septal defect. SVT: supraventricular tachycardia. PFO: patent foramen ovale. TOF: fallot tetralogy. SVT: supraventricular tachycardia. PVC: premature ventricular contraction. LQTs: long QT syndrome. SSS: sick sinus syndrome. WPW: Wolff–Parkinson–White syndrome. TdP: torsade de pointes. CPVT: Catecholamine sensitive ventricular tachycardia. PDA: patent ductus arteriosus. PLSVA: persistent left superior vena cava. PS: pulmonary stenosis. RVH: right ventricular hypertrophy. −, not mentioned in the previous reports. +, mentioned/occurred in previous reports

Table 4 The phenotypes of genes associated with left ventricular noncompaction in OMIM database

Location	Genes	Full name	Gene/locus MIM number	Phenotypes in OMIM	
12p12.1	ABCC9	ATP binding cassette subfamily C member 9	601439	AF; DCM; hypertrichotic osteochondrodysplasia	
15q14	ACTC1	Actin alpha cardiac muscle 1	102540	ASD; DCM; HCM; LVNC	
1q43	ACTN2	Actinin alpha 2	102573	DCM; HCM; LVNC; myopathy	
4q25-q26	ANK2	Ankyrin 2	106410	Cardiac arrhythmia; LQTs	
15q25.3	ALPK3	Alpha kinase 3	617608	HCM	
20q13.13	ARFGEF2	ADP ribosylation factor guanine nucleotide exchange factor 2	605371	Periventricular heterotopia with microcephaly	
10q26.11	BAG3	BAG cochaperone 3	603883	DCM; myofibrillar myopathy	
7q34	BRAF	B-Raf proto-oncogene, serine/threonine kinase	164757	Adenocarcinoma of lung, somatic; cardiofaciocutaneous syndrome; colorectal cancer, somatic; LEOPARD syndrome; melanoma, malignant, somatic; nonsmall cell lung cancer, somatic; Noonan syndrome	
2p13.3	BMP10	Bone morphogenetic protein 10	608748	–	
7q21.11	CACNA2D1	Calcium voltage-gated channel auxiliary subunit alpha2delta 1	–	–	
1p13.1	CASQ2	Calsequestrin 2	114251	CPVT	
1p36.22	CASZ1	Castor zinc finger 1	609895	–	
2q32.2	COL3A1	Collagen type III alpha 1 Chain	120180	Ehlers–Danlos syndrome, vascular type; polymicrogyria with or without vascular type Ehlers–Danlos syndrome	
2q35	DES	Desmin	125660	DCM; myofibrillar yopathy; Scapuloperoneal syndrome, neurogenic, kaeser type	
18q12.1	DSC2	Desmocollin2	125645	ACM; mild palmoplantar keratoderma and woolly hair	
6p24.3	DSP	Desmoplakin	125647	ACM; DCM; woolly hair and keratoderma; keratoderma and tooth agenesis; epidermolysis bullosa, lethal acantholytic; keratosis palmoplantaris striata II; Skin fragility-woolly hair syndrome	
18q12.1	DTNA	Dystrobrevin alpha	601239	LVNC; CHD	
Xq28	EMD	Emerin	300384	Emery-Dreifuss muscular dystrophy	
15q21.1	FBN1	Fibrillin 1	134797	Acromicric dysplasia; ectopia lentis, familial; geleophysic dysplasia; marfan lipodystrophy syndrome; Marfan syndrome; MASS syndrome; Stiff skin syndrome; Weill–Marchesani syndrome	
20p13	FKBP12	FKBP prolyl isomerase 1A	186945	–	
9q31.2	FKTN	Fukutin	607440	DCM; muscular dystrophy-dystroglycanopathy	
7q32.1	FLNC	Filamin C	102565	HCM; RCM; distal myopathy; myofibrillar myopathy	
2p23.3	HADHB	Hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta	143450	Trifunctional protein deficiency	
15q24.1	HCN4	Hyperpolarization activated cyclic nucleotide gated potassium channel 4	605206	Brugada syndrome; SSS	
6q22.31	HEY2	Hes related family bHLH transcription factor with YRPW motif 2	604674	–	
6p22.3	JARID2	Jumonji and AT-rich interaction domain containing 2	–	–	
8p23.1	GATA4	GATA binding protein 4	600576	Testicular anomalies with or without congenital heart disease; ASD; VSD; TOF	
11p15.5-p15.4	KCNQ1	Potassium voltage-gated channel subfamily Q member 1	607542/604115	LQTs; SQTs; AF; Jervell and Lange–Nielsen syndrome; Beckwith–Wiedemann syndrome	
7q36.1	KCNH2	Potassium voltage-gated channel subfamily H member 2	152427	LQTs	
Xq24	LAMP2	Lysosomal associated membrane protein 2	309060	Danon disease	
10q23.2	LDB3	LIM domain binding 3	605906	DCM; HCM; LVNC; myofibrillar myopathy	
1q22	LMNA	lamin A/C	150330	DCM; RCM; Charcot-Marie-Tooth disease; Emery-Dreifuss muscular dystrophy; Heart-hand syndrome; Hutchinson-Gilford progeria; lipodystrophy; Malouf syndrome; mandibuloacral dysplasia; muscular dystrophy	
15q26.3	MEF2A	Myocyte enhancer factor 2A	600660	Coronary artery disease	
1p34.1	MMACHC	Metabolism of cobalamin associated C	609831	Methylmalonic aciduria and homocystinuria	
18q11.2	MIB1	MIB E3 ubiquitin protein ligase 1	608677	LVNC	
1p36.33	MIB2	MIB E3 ubiquitin protein ligase 2	611141	–	
13q12.12	MIPEP	Mitochondrial intermediate peptidase	602241	Combined oxidative phosphorylation deficiency	
11p11.2	MYBPC3	Myosin binding protein C3	600958	DCM; HCM; LVNC	
16q23.3	MLYCD	Malonyl-CoA decarboxylase	606761	Malonyl-CoA decarboxylase deficiency	
14q11.2	MYH7	Myosin heavy chain 7	160760	DCM; HCM; LVNC; laing distal myopathy; myopathy, myosin storage; Scapuloperoneal syndrome	
20q11.21	MYLK2	Myosin light chain kinase 2	606566	HCM	
5q31.2	MYOT	Myotilin	604103	Myofibrillar myopathy; myopathy, spheroid body	
10p12.31	NEBL	Nebulette	605491	–	
5q35.1	NKX2.5	NK2 homeobox 5	600584	ASD; AVB; conotruncal heart malformations; Hypoplastic left heart syndrome; hypothyroidism, congenital nongoitrous; TOF; VSD	
1p31.1	NEXN	Nexilin F-actin binding protein	613121	DCM; HCM	
5p12	NNT	Nicotinamide nucleotide transhydrogenase	607878	Glucocorticoid deficiency with or without mineralocorticoid deficiency	
Xq13.1	NONO	Non-POU domain containing octamer binding	300084	Mental retardation	
8p12	NRG1	Neuregulin 1	142445	Schizophrenia	
5q35.3	NSD1	Nuclear receptor binding SET domain protein 1	606681	Sotos syndrome	
1q42.13	OBSCN	Obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF	–	–	
4q35.1	PDLIM3	PDZ and LIM domain 3	–	–	
12p11.21	PKP2	Plakophilin 2	602861	ACM	
1p36.21	PLEKHM2	Pleckstrin homology and RUN domain containing M2	609613	–	
3q22.1	PLXND1	Plexin D1	604282	–	
6q22.31	PLN	Phospholamban	172405	HCM; DCM	
1p36.32	PRDM16	PR/SET domain 16	605557	DCM; LVNC	
12q24.13	PTPN11	Protein tyrosine phosphatase non-receptor type 11	176876	LEOPARD syndrome; leukemia, juvenile myelomonocytic, somatic; metachondromatosis; Noonan syndrome	
10q25.2	RBM20	RNA binding motif protein 20	613171	DCM	
Xp22.12	RPS6KA3	Ribosomal protein S6 kinase A3	300075	Coffin–Lowry syndrome; mental retardation	
1q43	RYR2	Ryanodine receptor 2	180902	ACM; CPVT	
3p22.2	SCN5A	Sodium voltage-gated channel alpha subunit 5	600163	Sudden infant death syndrome; AF; Brugada syndrome; DCM; LQTs; SSS; VF	
11q23.1	SDHD	Succinate dehydrogenase complex subunit D	602690	Mitochondrial complex II deficiency; araganglioma and gastric stromal sarcoma; paragangliomas with or without deafness	
16p11.2	SH2B1	SH2B adaptor protein 1	608937	–	
4q24	SLC39A8	Solute carrier family 39 member 8	608732	Congenital disorder of glycosylation	
Xp11.22	SMC1A	Structural maintenance of chromosomes 1A	300040	Cornelia de Lange syndrome; developmental and epileptic encephalopathy, with or without midline brain defects	
15q24.1	STRA6	Signaling receptor and transporter of retinol STRA6	610745	Microphthalmia with coloboma; Microphthalmia, syndromic	
X A7.3; X 37.95 cM	TAZ	Tafazzin	300394	Barth syndrome	
12q24.21	TBX5	T-box transcription factor 5	601620	Holt–Oram syndrome	
7p14.2	TBX20	T-box transcription factor 20	606061	ASD	
3p25.1	TMEM43	Transmembrane protein 43	612048	ACM; Emery-Dreifuss muscular dystrophy	
8q21.11	TMEM70	Transmembrane protein 70	612418	Mitochondrial complex V (ATP synthase) deficiency, nuclear type	
3p21.1	TNNC1	Troponin C1, slow skeletal and cardiac type	191040	DCM; HCM	
19q13.42	TNNI3	Troponin I3, cardiac type	191044	DCM; RCM; HCM	
1q32.1	TNNT2	Troponin T2, cardiac type	191045	DCM; RCM; HCM; LVNC	
15q22.2	TPM1	tropomyosin 1	191010	DCM; HCM; LVNC	
2q31.2	TTN	Titin	188840	DCM; HCM; muscular dystrophy, limb-girdle; myofibrillar myopathy with early respiratory failure; salih myopathy; tibial muscular dystrophy, tardive	
17p13.3	YWHAE	Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon	605066	–	
LVNC: left ventricular noncompaction. HCM: hypertrophic cardiomyopathy. DCM: dilated cardiomyopathy. ACM: arrhythmogenic cardiomyopathy. RCM: restricted cardiomyopathy. AF: atrial fibrillation. ASD: atrial septal defect. CHD: congenital heart disease. VSD: ventricular septal defect. PFO: patent foramen ovale. TOF: fallot tetralogy. LQTs: long QT syndrome. SQTs: short QT syndrome. SSS: sick sinus syndrome. WPW: Wolff–Parkinson–White syndrome. CPVT: catecholamine sensitive ventricular tachycardia. VF: ventricular fibrillation. PDA: patent ductus arteriosus. –, not mentioned in OMIM database

Expression of DSC2

The western blot (Fig. 5) showed that the expressing level of functional desmocollin2 protein (~ 94kd) was lower in the proband than that in the healthy volunteer, indicating that DSC2 p.K47Rfs*2 remarkably and abnormally reduced the functional desmocollin2 expression in the proband.Fig. 5 The expression of desmocollin2. NS: normal control (the healthy volunteer). The samples of NS and DSC2 p.K47Rfs*2 were collected from the skin and subcutaneous tissue in the upper left limb of the healthy volunteer and the proband (II: 1)

Discussion

In our study, we have first discovered that the truncated mutation (p.K47Rfs*2) of DSC2 remarkably and abnormally reduced the functional desmocollin2 expression, as an important component of desmosome assembly, which may consequently induce rare overlap phenotypes of LVNC and HCM, complicating AF, VT, and HF.

LVNC is a rare primary CM and serves as a global cardiac disease induced by the arrest of normal embryogenesis of the endocardium and mesocardium that leads to prominent trabeculations and deep intertrabecular recesses within the LV wall communicating with the cavity, a thin compacted epicardial layer, and acquired ventricular wall remodeling [24]. The inferior and lateral walls of LV from the midcavity to the apex are the most commonly involved [10]. The Jenni and Petersen diagnosis criteria of LVNC are generally accepted and rely on imaging modalities, including echocardiography and CMRI, e.g., (1) bilayer myocardium with multiple, prominent trabeculations in the end-systole; (2) NC/C ratio of > 2:1 in echocardiography or > 2.3 in CMRI measured in the end-systole or end-diastole, respectively; and (3) communication with the intertrabecular space and deep intertrabecular recesses in the noncompaction layer [10, 11]. Based on previous studies [25] and our literature review, the LVNC prevalence is 0.05%–0.3% in an adult population undergoing echocardiography. LVNC may occur with congenital heart malformations, myopathies, neuromuscular and metabolic diseases, complicating developmental delay and intellectual disability. LVNC with HF, ventricular arrhythmias, and thromboembolic events show poor prognosis with an overall mortality rate of 5–12% per year [26]. As shown in the literature review in our study, once the cases occur with LVNC and malignant clinical syndromes, the prognosis is poor with high mortality in the fetus or infant. Some LVNC patients have a family history of LVNC and/or sudden death and recurrent VT despite therapy with multiple antiarrhythmic drugs. The ventricular arrhythmia ordinarily originates from bilateral ventricles. The substrate of ventricular arrhythmia in LVNC typically involves the mid-apical segment, septum, and lateral wall of LV. In contrast, focal PVCs commonly arise from LV basal-septal regions and/or papillary muscles, reflecting the distribution of noncompaction myocardial segments [27]. LVNC mostly affects the left ventricular muscle and serves as a primary and genetically heterogeneous CM, which the American Heart Association exists in sporadic and hereditary forms. Previous research showed that among LVNC cases, 52% are sporadic, 32% have a genetic cause, and an additional 16% have affected family members with negative genetic testing. Not all family members present with the same LVNC phenotype as some proband occurs with DCM, HCM, or SCD [28]. Potentially causative gene mutations responsible for LVNC are involved in the sarcomere, cytoskeleton, mitochondria, desmosome, and storage and ion channels implicated in other cardiac diseases [29–31]. According to previous studies and our literature review, MYH7, MYBPC3, TPM1, TAZ, TTN, and NONO genes are the most common pathogenic mutations in LVNC [28, 32, 33], which are not demonstrated in the proband of our study. LVNC or an element of other CMs may be isolated due to sharing common genetic risk [34]. These common genetic backgrounds are phenotypically expressed as overlap CMs, fulfilling the criteria for LVNC and HCM (or DCM, RCM, or ACM). The LV hypertrabeculation and HCM may present as acquired conditions due to the adaptation of the ventricular myocardium to pressure or volume overload [35]. Some LVNCs also involve the right ventricle, exhibiting high values of right ventricular noncompaction and trabeculated area [36]. Therefore, the subtypes of LVNC include benign LVNC, LVNC with arrhythmias, dilated LVNC, hypertrophic LVNC, hypertrophic dilated LVNC, restrictive LVNC, right ventricular or biventricular LVNC, and LVNC with CHD [25]. Actually, some pathogenic mutations are associated with various complex rare diseases involving more than one organ. For example, the 11-16th exon deletion of KCNQ1 induced mild Beckwith-Wiedemann and severe LQTs [37]. Notably, in light of our literature review, LVNC with complex clinical syndromes, poor prognosis, and high mortality that may occur in the fetus or infant should be classified as another new subtype of LVNC. These syndromes may include Rubinstein–Taybi syndrome, Ehlers–Danlos syndrome, Emery–Deifuss muscular dystrophy, Danon disease, intellectual disability syndrome, Soto’s syndrome, LEOPARD syndrome, Coffin-Lowry syndrome, Cornelia de Lange syndrome, Barth syndrome, and Holt–Oram syndrome.

Two independent biological events leading to abnormal trabeculations and compaction, including hypertrabeculation and noncompaction, are demonstrated by the FKBP12-deficient mouse model for LVNC [38, 39]. Hypertrabeculation refers to the phenotype with increased number and thickness of the trabeculae at the embryonic stage. In contrast, noncompaction refers to the lack of trabecular remodeling toward the compact wall during and after trabeculations [40]. The enhanced Notch signaling induces abnormal cardiomyocyte proliferation and hypertrabeculation/noncompaction via Neuregulin1, EphrinB2, FKBP12, BMP10, TBX20 and its upstream of Sema3E/PlexinD1 signaling pathway, which potentially contributes to LVNC [41, 42]. The inhibition of Notch signaling partly normalizes the abnormal hypertrabeculation phenotype in FKBP12-deficient hearts. The planar cell polarity (PCP) signaling is also an essential molecular mechanism of polarity establishment for epithelial cells in planes orthogonal to the apical-basal axis. The noncanonical Wnt signaling, which is independent of β-catenin, is critical for PCP signaling. Together, they serve as the Wnt/PCP signaling pathway, which is composed of core components (i.e., Frizzled, Disheveled, Prickle, Vangl, and Celsr1), PCP regulator (i.e., casein kinase 1ε) and a large number of PCP effectors (i.e., Daam1, Rac1, and PhoA) [43, 44]. These molecules of Wnt/PCP signaling induced by their genetic mutations result in abnormal polarization, organization of cardiomyocyte in ventricular and outflow myocardia, and subsequent LVNC pathogenesis [40].

In this study, the proband (II: 1) carried DSC2 p.K47Rfs*2 and p.I520T variants. According to the ACMG classification criteria, the DSC2 p.K47Rfs*2 is a truncated and loss-of-function mutation, likely to cause LVNC and HCM. Compared to the MAF (< 0.01%) of inherited arrhythmia and CMs in the population, the MAF of DSC2 p.I520T (0.02%) is relatively high. Moreover, DSC2 p.I520T is not conservative in multiple species. In addition, the ECG is the main tool to judge the early changes of CMs. Especially, the abnormal changes of ECG caused by CMs are often earlier than that of the cardiac structure illustrated by echocardiography [45]. Whereas II: 3 only carrying DSC2 p.I520T and without cardiac event showed normal ECG and echocardiography. Therefore, we speculated that DSC2 p.I520T might not be pathogenic. In fact, as an important component of the cardiac desmosome, desmocollin2 maintains the normal electromechanical connection among cardiomyocytes. The desmocollin2 abnormality would lead to various CMs (such as DCM and HCM), HF, complex arrhythmia and even SCD. Recent research and our literature review showed that the abnormal components of the cardiac desmosome, including DES and DSP genes, are associated with LVNC. Desmosome is the intracellular structure that anchors intermediate filament to the plasma membrane. Desmosome, adherent junction, and gap junction are the major components of the intercalated disc, which is vital for the cell–cell adhesion and electronic coupling of cardiomyocytes [46]. Desmocollin2 and desmoglein2 (encoded by DSG2) are the important familial members of cadherin. Desmocollin2 and desmoglein2 form the adhesive heterodimer, which provides a structural framework for desmosome assembly together with armadillo proteins (plakoglobin and plakophilin, which are encoded by PG and PKP2, respectively) and the plakin family (desmoplakin, which DSP encodes) [47, 48]. The desmin filament (encoded by DES), also expressed in cardiac desmosomes, connects Z-bands, costameres, and nuclei with the cytoskeleton. The pathogenic mutations associated with desmosome proteins may cause desmosome dysfunction and remodel intercalated disc, leading to the disturbance of the mechanical–electrical coupling of cell–cell adhesion and further alteration of signaling pathways.

Previous studies show that the homozygous deletion mutation of PKP2 lead to LVNC and rapid HF, whereas the heterozygous DES p.A337P (NM_001927.3, c.1009G>C) induces LVNC and skeletal myopathy [49, 50]. A report indicates a DSC2 variant (NM_024422.3, c.1448A>T, p.N483I) in a patient with sporadic LVNC, but whether the variant is the cause of LVNC remains unclear [32]. A previous study shows that the DSC2 deletion in zebrafish induces the reduction of the desmosome plaque area, deficiency of desmosome extracellular electron-dense midlines, and disturbance of myocardial contractility [51]. Additionally, DSC2 p.Q554X (c.1660C>T) participates in the pathogenicity of familial ACM [52]. DSC2 p.A897fs*900 shows an obvious reduction in desmosome binding to plakoglobin and plakophilin [53]. The truncated mutation of DSC2 (c.2553delA) decreases the connexin 43 expression and lost plakoglobin signal [54]. Furthermore, the loss of DSC2 activates the AKT/β-catenin pathway. AKT inhibition suppresses β-catenin-dependent transcription and proliferation, which are caused by DSC2 knockdown [55]. In the present study, the 47th AA lysine of the DSC2 protein sequence at the cadherin pro is replaced by arginine, leading to premature codon termination. Consequently, DSC2 p.K47Rfs*2 remarkably and abnormally reduced the functional desmocollin2 expression, which may interfere with desmosome formation and the stability of the intermediated disc, and disturb the mechanical stress and electrical signal propagation of cardiomyocytes. Notably, the pathological and imaging changes induced by DSC2 p.K47Rfs*2 are observed in LV, resulting in the subendocardial thickening of the anterior lateral wall and interventricular septum, and thinning in part of the left ventricular wall. The ECG of the proband showed low voltage in the limb leads but no typical ST-T change, commonly suggesting diffuse myocardial lesion. The VT arises from the middle-posterior septum and lateral wall of LV. PVCs originate from the lateral wall and apex of LV and the left ventricular inflow tract, and this finding is consistent with the cardiac lesion extent. Additionally, trabeculae are observed with serious dysplasia and distributed in a rough and disordered pattern. An apparent slow blood flow is observed in the recess of trabeculae, which may increase the risk of thrombus. However, the mechanism of DSC2 p.K47Rfs*2 that induces overlap phenotypes of LVNC and HCM remains unknown. There is no research about the relationship among DSC2, Notch, and Wnt/PCP signaling pathways.

Limitation

The limitations of the present study are as follows. First, the molecular mechanism of DSC2 p.K47Rfs*2 leading to abnormalities of the desmosome structure and function should be further explored. Second, DSC2 p.K47Rfs*2 is the main cause of LVNC and HCM but still cannot rule out DSC2 p.I520T, or other variants may increase the risk of LVNC and HCM phenotype penetrance. Third, the mechanism of how the DSC2 p.K47Rfs*2 induces overlap phenotypes needs further research. Fourth, the parents and grandparents of the patient (II: 1) could not be tracked because of death. The II: 1, II: 2 and II: 3 members declined to to carry out clinical examinations and genetic testing for their offspring. Therefore, long-term follow-up is needed in the future.

Conclusion

The desmocollin2 was an important component of cardiac desmosome assembly, of which abnormality caused the dysfunction of cell–cell adhesions and intercellular gap junctions. The novel heterozygous DSC2 p.K47Rfs*2 mutation remarkably and abnormally reduced the functional desmocollin2 expression, which may consequently induce the overlap phenotypes of LVNC and HCM, complicating AF, VT, and HF. The LVNC may be one of the important phenotypes for DSC2 pathogenic mutations.

Abbreviations

CM Cardiomyopathy

LVNC Left ventricular noncompaction cardiomyopathy

HCM Hypertrophic cardiomyopathy

DCM Dilated cardiomyopathy

RCM Restrictive cardiomyopathy

ACM Arrhythmogenic cardiomyopathy

AF Atrial fibrillation

VT Ventricular tachycardia

HF Heart failure

SCD Sudden cardiac death

LVEF Left ventricular ejection fraction

MYH7 Myosin heavy chain

MYBPC3 Protein-binding protein C myosin

TPM1 Tropomyosin alfa

ACTC1 Myocardial actin

TNNT2 Troponin T

DTNA Alpha-distrobrevin

CMRI Cardiac magnetic resonance imaging

ECGs Electrocardiograms

NT-proBNP The N-terminal of B-type natriuretic peptide precursor

LV Left ventricle

Acknowledgements

The authors thank YanYan from the molecular image center in the Fifth Affiliated Hospital of Sun Yat-sen University for the Manuscript’s Critical Comments and advice. We are grateful to Jinsheng Tao, Jia Li, BGI (Shenzhen, China) and TSINGKE Biological Technology (Guangzhou, China) for technical assistance.

Authors' contributions

Statistical analysis and manuscript drafting, Y.B.L. and J.N.H.; clinical data, family information and follow-up, Z.L.Z. and X.F.L.; designed the study and critical manuscript revision, Z.Y.H. and G.Y.X.; radiography analysis, Z.Q.Z.; echocardiogram analysis, J.Z.X.; western-blot and PCR experiments, T.F.Q, L.X.C. and J.M.H.; electrocardiogram analysis, Q.Y.W and Y.H. All authors read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China [81970332], the Science and Technology Project of Zhuhai [20191210E030072], and the Medical Science and Technology Research Project of Guangdong Province [A2018043].

Availability of data and materials

The data used in this study is not publicly available, but it might be available from the corresponding author upon reasonable request and permission from relevant Chinese Authorities.

Declarations

Ethics approval

All procedures performed in studies involving human participants were following the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The Medicine Ethics Committee approved the protocol of the Fifth Affiliated Hospital of Sun Yat-sen University (No. 2020K216-1).

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Consent for publication

Not applicable.

Competing interests

The authors of this study declare that they each have no conflict of interest.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Yubi Lin, Jiana Huang and Zhiling Zhu have contributed equally
==== Refs
References

1. Ross SB Singer ES Driscoll E Genetic architecture of left ventricular noncompaction in adults Hum Genome Var 2020 7 33 33082984
2. Arbustini E Favalli V Narula N Serio A Grasso M Left ventricular noncompaction: a distinct genetic cardiomyopathy J Am Coll Cardiol 2016 68 9 949 966 27561770
3. Ayesha B Ahmed R Gomceli U Manrique C Nicu M Chilimuri S A case of isolated left ventricular non-compaction cardiomyopathy in a HIV patient presenting with acute heart failure Cardiol Res 2019 10 4 236 240 31413781
4. Sánchez Muñoz JJ, Esparza CM, Verdú PP, et al. Catheter ablation of ventricular arrhythmias in left ventricular noncompaction cardiomyopathy. Heart Rhythm. 2020.
5. Martinez A Omar M Kandah F Ruiz J Niazi A Left ventricular non-compaction presenting as cardio-embolic stroke J Geriatr Cardiol 2020 17 10 645 646 33224185
6. Aung N Doimo S Ricci F Prognostic significance of left ventricular noncompaction: systematic review and meta-analysis of observational studies Circ Cardiovasc Imaging 2020 13 1 e009712 31959004
7. Filho D, do Rêgo Aquino PL, de Souza Silva G, Fabro CB. Left ventricular noncompaction: new insights into a poorly understood disease. Curr Cardiol Rev. 2020.
8. Guo J Li Z Hao C A novel de novo CASZ1 heterozygous frameshift variant causes dilated cardiomyopathy and left ventricular noncompaction cardiomyopathy Mol Genet Genomic Med 2019 7 8 e828 31268246
9. Vershinina T Fomicheva Y Muravyev A Genetic spectrum of left ventricular non-compaction in paediatric patients Cardiology 2020 145 11 746 756 33049752
10. Jenni R Oechslin E Schneider J Attenhofer Jost C Kaufmann PA Echocardiographic and pathoanatomical characteristics of isolated left ventricular non-compaction: a step towards classification as a distinct cardiomyopathy Heart 2001 86 6 666 671 11711464
11. Petersen SE Selvanayagam JB Wiesmann F Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging J Am Coll Cardiol 2005 46 1 101 105 15992642
12. Dong C Wei P Jian X Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies Hum Mol Genet 2015 24 8 2125 2137 25552646
13. Li Q Wang K InterVar: clinical interpretation of genetic variants by the 2015 ACMG-AMP guidelines Am J Hum Genet 2017 100 2 267 280 28132688
14. Richards S Aziz N Bale S Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology Genet Med 2015 17 5 405 424 25741868
15. Lin Y Huang J Zhao T He S Huang Z Chen X Fei H Luo H Liu H Wu S Lin X Compound and heterozygous mutations of DSG2 identified by Whole Exome Sequencing in arrhythmogenic right ventricular cardiomyopathy/dysplasia with ventricular tachycardia J Electrocardiol 2018 51 837 843 30177324
16. Lek M Karczewski KJ Minikel EV Samocha KE Banks E Fennell T Donnell-Luria AH Ware JS Hill AJ Analysis of protein-coding genetic variation in 60,706 humans Nature 2016 536 285 291 27535533
17. Kobayashi Y Yang S Nykamp K Garcia J Lincoln SE Topper SE Pathogenic variant burden in the ExAC database: an empirical approach to evaluating population data for clinical variant interpretation Genome Med 2017 9 13 28166811
18. Abou Tayoun AN Pesaran T DiStefano MT Oza A Rehm HL Biesecker LG Harrison SM Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion Hum Mutat 2018 39 1517 1524 30192042
19. Sarquella-Brugada G, Fernandez-Falgueras A, Cesar S, Arbelo E, Coll M, Perez-Serra A, Puigmulé M, Iglesias A, Alcalde M, Vallverdú-Prats M, et al. Clinical impact of rare variants associated with inherited channelopathies: a 5-year update. Hum. Genet. 2021.
20. Campuzano O Sarquella-Brugada G Fernandez-Falgueras A Coll M Iglesias A Ferrer-Costa C Cesar S Arbelo E García-Álvarez A Jordà P Reanalysis and reclassification of rare genetic variants associated with inherited arrhythmogenic syndromes EBioMedicine 2020 54 102732 32268277
21. Musunuru K Hershberger RE Day SM Klinedinst NJ Landstrom AP Parikh VN Prakash S Semsarian C Sturm AC Genetic testing for inherited cardiovascular diseases: a scientific statement from the American Heart Association Circ Genom Precis Med 2020 13 e000067 32698598
22. Lahrouchi N Raju H Lodder EM Papatheodorou E Ware JS Papadakis M Tadros R Cole D Skinner JR Crawford J Utility of post-mortem genetic testing in cases of sudden arrhythmic death syndrome J Am Coll Cardiol 2017 69 2134 2145 28449774
23. Costa S, Cerrone M, Saguner AM, Brunckhorst C, Delmar M, Duru F. Arrhythmogenic cardiomyopathy: An in-depth look at molecular mechanisms and clinical correlates. Trends Cardiovasc Med. 2020.
24. Arunamata A Stringer J Balasubramanian S Tacy TA Silverman NH Punn R Cardiac segmental strain analysis in pediatric left ventricular noncompaction cardiomyopathy J Am Soc Echocardiogr 2019 32 6 763 773.e1 30926406
25. Towbin JA Lorts A Jefferies JL Left ventricular non-compaction cardiomyopathy Lancet 2015 386 9995 813 825 25865865
26. Finsterer J Stöllberger C Towbin JA Left ventricular noncompaction cardiomyopathy: cardiac, neuromuscular, and genetic factors Nat Rev Cardiol 2017 14 4 224 237 28079110
27. Muser D Liang JJ Witschey WR Ventricular arrhythmias associated with left ventricular noncompaction: electrophysiologic characteristics, mapping, and ablation Heart Rhythm 2017 14 2 166 175 27890738
28. van Waning JI Caliskan K Hoedemaekers YM Genetics, clinical features, and long-term outcome of noncompaction cardiomyopathy J Am Coll Cardiol 2018 71 7 711 722 29447731
29. Abela M D'Silva A Left ventricular trabeculations in athletes: epiphenomenon or phenotype of disease Curr Treat Options Cardiovasc Med 2018 20 12 100 30367273
30. Nozaki Y Kato Y Uike K Co-phenotype of left ventricular non-compaction cardiomyopathy and atypical catecholaminergic polymorphic ventricular tachycardia in association with R169Q, a ryanodine receptor type 2 missense mutation Circ J 2020 84 2 226 234 31875585
31. Precone V Krasi G Guerri G Cardiomyopathies Acta Biomed 2019 90 10-S 32 43 31577251
32. Richard P Ader F Roux M Targeted panel sequencing in adult patients with left ventricular non-compaction reveals a large genetic heterogeneity Clin Genet 2019 95 3 356 367 30471092
33. Sedaghat-Hamedani F Haas J Zhu F Clinical genetics and outcome of left ventricular non-compaction cardiomyopathy Eur Heart J 2017 38 46 3449 3460 29029073
34. Vergani V Lazzeroni D Peretto G Bridging the gap between hypertrabeculation phenotype, noncompaction phenotype and left ventricular noncompaction cardiomyopathy J Cardiovasc Med (Hagerstown) 2020 21 3 192 199 31895132
35. Di Fusco SA Lucà F Madeo A Left ventricular noncompaction: diagnostic approach, prognostic evaluation, and management strategies Cardiol Rev 2020 28 3 125 134 31008770
36. Stämpfli SF, Gotschy A, Kiarostami P, et al. Right ventricular involvement in left ventricular non-compaction cardiomyopathy. Cardiol J. 2020.
37. Gurrieri F Zollino M Oliva A Pascali V Orteschi D Pietrobono R Camporeale A Coll Vidal M Partemi S Brugada R Mild Beckwith–Wiedemann and severe long-QT syndrome due to deletion of the imprinting center 2 on chromosome 11p Eur J Hum Genet 2013 21 965 969 23511928
38. Chen H Zhang W Sun X Fkbp1a controls ventricular myocardium trabeculation and compaction by regulating endocardial Notch1 activity Development 2013 140 9 1946 1957 23571217
39. Shou W Aghdasi B Armstrong DL Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12 Nature 1998 391 6666 489 492 9461216
40. Zhang W Chen H Qu X Chang CP Shou W Molecular mechanism of ventricular trabeculation/compaction and the pathogenesis of the left ventricular noncompaction cardiomyopathy (LVNC) Am J Med Genet C Semin Med Genet 2013 163C 3 144 156 23843320
41. Grego-Bessa J Luna-Zurita L del Monte G Notch signaling is essential for ventricular chamber development Dev Cell 2007 12 3 415 429 17336907
42. Sandireddy R, Cibi DM, Gupta P, et al. Semaphorin 3E/PlexinD1 signaling is required for cardiac ventricular compaction. JCI Insight. 2019;4(16).
43. Simons M Mlodzik M Planar cell polarity signaling: from fly development to human disease Annu Rev Genet 2008 42 517 540 18710302
44. Wang Y Nathans J Tissue/planar cell polarity in vertebrates: new insights and new questions Development 2007 134 4 647 658 17259302
45. Shimizu M Ino H Yamaguchi M Terai H Hayashi K Kiyama M Sakata K Hayashi T Inoue M Kaneda T Chronologic electrocardiographic changes in patients with hypertrophic cardiomyopathy associated with cardiac troponin 1 mutation Am Heart J 2002 143 289 293 11835033
46. Vermij SH Abriel H van Veen TA Refining the molecular organization of the cardiac intercalated disc Cardiovasc Res 2017 113 3 259 275 28069669
47. Garrod D Chidgey M Desmosome structure, composition and function Biochim Biophys Acta 2008 1778 3 572 587 17854763
48. Getsios S Amargo EV Dusek RL Coordinated expression of desmoglein 1 and desmocollin 1 regulates intercellular adhesion Differentiation 2004 72 8 419 433 15606501
49. Kulikova O, Brodehl A, Kiseleva A, et al. The desmin (DES) mutation p.A337P is associated with left-ventricular non-compaction cardiomyopathy. Genes (Basel). 2021;12(1).
50. Ramond F Janin A Di Filippo S Homozygous PKP2 deletion associated with neonatal left ventricle noncompaction Clin Genet 2017 91 1 126 130 27030002
51. Heuser A Plovie ER Ellinor PT Mutant desmocollin-2 causes arrhythmogenic right ventricular cardiomyopathy Am J Hum Genet 2006 79 6 1081 1088 17186466
52. Gerull B Kirchner F Chong JX Tagoe J Chandrasekharan K Strohm O Waggoner D Ober C Duff HJ Homozygous founder mutation in desmocollin-2 (DSC2) causes arrhythmogenic cardiomyopathy in the Hutterite population Circ Cardiovasc Genet 2013 6 327 336 23863954
53. Gehmlich K Syrris P Peskett E Mechanistic insights into arrhythmogenic right ventricular cardiomyopathy caused by desmocollin-2 mutations Cardiovasc Res 2011 90 1 77 87 21062920
54. Gehmlich K Lambiase PD Asimaki A A novel desmocollin-2 mutation reveals insights into the molecular link between desmosomes and gap junctions Heart Rhythm 2011 8 5 711 718 21220045
55. Kolegraff K Nava P Helms MN Parkos CA Nusrat A Loss of desmocollin-2 confers a tumorigenic phenotype to colonic epithelial cells through activation of Akt/β-catenin signaling Mol Biol Cell 2011 22 8 1121 1134 21325624
56. Semsarian C Ingles J Molecular autopsy in victims of inherited arrhythmias J Arrhythm 2016 32 359 365 27761159
57. Dunn KE Caleshu C Cirino AL Ho CY Ashley EA A clinical approach to inherited hypertrophy: the use of family history in diagnosis, risk assessment, and management Circ Cardiovasc Genet 2013 6 118 131 23424256
58. Waldmüller S Schroeder C Sturm M Targeted 46-gene and clinical exome sequencing for mutations causing cardiomyopathies Mol Cell Probes 2015 29 5 308 314 25979592
59. Frustaci A, De Luca A, Guida V, et al. Novel α-actin gene mutation p.(Ala21Val) causing familial hypertrophic cardiomyopathy, myocardial noncompaction, and transmural crypts. Clinical-pathologic correlation. J Am Heart Assoc. 2018;7(4).
60. Smith J Owen T Bhagwan JR Isogenic pairs of hiPSC-CMs with hypertrophic cardiomyopathy/LVNC-associated ACTC1 E99K mutation unveil differential functional deficits Stem Cell Reports 2018 11 5 1226 1243 30392975
61. Arad M Penas-Lado M Monserrat L Gene mutations in apical hypertrophic cardiomyopathy Circulation 2005 112 18 2805 2811 16267253
62. Klaassen S Probst S Oechslin E Mutations in sarcomere protein genes in left ventricular noncompaction Circulation 2008 117 22 2893 2901 18506004
63. Monserrat L Barriales-Villa R Hermida-Prieto M Apical hypertrophic cardiomyopathy and left ventricular non-compaction: two faces of the same disease Heart 2008 94 10 1253 18801786
64. Monserrat L Hermida-Prieto M Fernandez X Mutation in the alpha-cardiac actin gene associated with apical hypertrophic cardiomyopathy, left ventricular non-compaction, and septal defects Eur Heart J 2007 28 16 1953 1961 17611253
65. Takasaki A Hirono K Hata Y Sarcomere gene variants act as a genetic trigger underlying the development of left ventricular noncompaction Pediatr Res 2018 84 5 733 742 30188508
66. Rodríguez-Serrano M Domingo D Igual B Cano A Medina P Zorio E Familial left ventricular noncompaction associated with a novel mutation in the alpha-cardiac actin gene Rev Esp Cardiol (Engl Ed) 2014 67 10 857 859 25201647
67. Sheikh N Papadakis M Wilson M Diagnostic yield of genetic testing in young athletes with T-wave inversion Circulation 2018 138 12 1184 1194 29764897
68. Tian T Wang J Wang H A low prevalence of sarcomeric gene variants in a Chinese cohort with left ventricular non-compaction Heart Vessels 2015 30 2 258 264 24691700
69. Girolami F Iascone M Tomberli B Novel α-actinin 2 variant associated with familial hypertrophic cardiomyopathy and juvenile atrial arrhythmias: a massively parallel sequencing study Circ Cardiovasc Genet 2014 7 6 741 750 25173926
70. Park J Cho YG Park HW Cho JS Case report: novel likely pathogenic ACTN2 variant causing heterogeneous phenotype in a Korean family with left ventricular non-compaction Front Pediatr 2021 9 609389 33859969
71. Al Senaidi K Joshi N Al-Nabhani M Phenotypic spectrum of ALPK3-related cardiomyopathy Am J Med Genet A 2019 179 7 1235 1240 31074094
72. Yilmaz S Gokben S Serdaroglu G The expanding phenotypic spectrum of ARFGEF2 gene mutation: cardiomyopathy and movement disorder Brain Dev 2016 38 1 124 127 26126837
73. Hirono K Saito K Munkhsaikhan U Familial left ventricular non-compaction is associated with a rare p..V407I variant in bone morphogenetic protein 10 Circ J 2019 83 8 1737 1746 31243186
74. Chen H Shi S Acosta L BMP10 is essential for maintaining cardiac growth during murine cardiogenesis Development 2004 131 9 2219 2231 15073151
75. Cataldo S Annoni GA Marziliano N The perfect storm? Histiocytoid cardiomyopathy and compound CACNA2D1 and RANGRF mutation in a baby Cardiol Young 2015 25 1 174 176 24438356
76. Hoedemaekers YM Caliskan K Michels M The importance of genetic counseling, DNA diagnostics, and cardiologic family screening in left ventricular noncompaction cardiomyopathy Circ Cardiovasc Genet 2010 3 3 232 239 20530761
77. Darcha C, Laffargue F, Boutaud L, et al. Novel CDK10 variants with multicystic dysplastic kidney, left ventricular non-compaction, and a solitary median maxillary central incisor. Clin Genet. 2021.
78. Lan N Fietz M Pachter N Paul V Playford D A case of vascular Ehlers–Danlos Syndrome with a cardiomyopathy and multi-system involvement Cardiovasc Pathol 2018 35 48 51 29778910
79. Brodehl A Gaertner-Rommel A Milting H Molecular insights into cardiomyopathies associated with desmin (DES) mutations Biophys Rev 2018 10 4 983 1006 29926427
80. Miszalski-Jamka K, Jefferies JL, Mazur W, et al. Novel genetic triggers and genotype-phenotype correlations in patients with left ventricular noncompaction. Circ Cardiovasc Genet. 2017;10(4).
81. Marakhonov AV Brodehl A Myasnikov RP Noncompaction cardiomyopathy is caused by a novel in-frame desmin (DES) deletion mutation within the 1A coiled-coil rod segment leading to a severe filament assembly defect Hum Mutat 2019 40 6 734 741 30908796
82. Tamiya R Saito Y Fukamachi D Desmin-related myopathy characterized by non-compaction cardiomyopathy, cardiac conduction defect, and coronary artery dissection ESC Heart Fail 2020 7 3 1338 1343 32142595
83. López-Ayala JM Gómez-Milanés I Sánchez Muñoz JJ Desmoplakin truncations and arrhythmogenic left ventricular cardiomyopathy: characterizing a phenotype Europace 2014 16 12 1838 1846 24938629
84. Williams T Machann W Kühler L Novel desmoplakin mutation: juvenile biventricular cardiomyopathy with left ventricular non-compaction and acantholytic palmoplantar keratoderma Clin Res Cardiol 2011 100 12 1087 1093 21789513
85. Cao Q Shen Y Liu X Phenotype and functional analyses in a transgenic mouse model of left ventricular noncompaction caused by a DTNA mutation Int Heart J 2017 58 6 939 947 29118297
86. Ichida F Left ventricular noncompaction Circ J 2009 73 1 19 26 19057090
87. Ichida F Tsubata S Bowles KR Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome Circulation 2001 103 9 1256 1263 11238270
88. Xing Y Ichida F Matsuoka T Genetic analysis in patients with left ventricular noncompaction and evidence for genetic heterogeneity Mol Genet Metab 2006 88 1 71 77 16427346
89. Ishikawa T Mishima H Barc J Cardiac emerinopathy: a nonsyndromic nuclear envelopathy with increased risk of thromboembolic stroke due to progressive atrial standstill and left ventricular noncompaction Circ Arrhythm Electrophysiol 2020 13 10 e008712 32755394
90. Parent JJ Towbin JA Jefferies JL Fibrillin-1 gene mutations in left ventricular non-compaction cardiomyopathy Pediatr Cardiol 2016 37 6 1123 1126 27160103
91. Amiya E Morita H Hatano M Fukutin gene mutations that cause left ventricular noncompaction Int J Cardiol 2016 222 727 729 27521547
92. Ader F De Groote P Réant P FLNC pathogenic variants in patients with cardiomyopathies: prevalence and genotype-phenotype correlations Clin Genet 2019 96 4 317 329 31245841
93. Tang VT Arscott P Helms AS Day SM Whole-exome sequencing reveals GATA4 and PTEN mutations as a potential digenic cause of left ventricular noncompaction Circ Genom Precis Med 2018 11 1 e001966 29874181
94. Ojala T Nupponen I Saloranta C Fetal left ventricular noncompaction cardiomyopathy and fatal outcome due to complete deficiency of mitochondrial trifunctional protein Eur J Pediatr 2015 174 12 1689 1692 26070998
95. Alonso-Fernández-Gatta M, Gallego-Delgado M, Caballero R, et al. A rare HCN4 variant with combined sinus bradycardia, left atrial dilatation, and hypertrabeculation/left ventricular noncompaction phenotype. Rev Esp Cardiol (Engl Ed). 2020.
96. Milano A Vermeer AM Lodder EM HCN4 mutations in multiple families with bradycardia and left ventricular noncompaction cardiomyopathy J Am Coll Cardiol 2014 64 8 745 756 25145517
97. Ishikawa T Ohno S Murakami T Sick sinus syndrome with HCN4 mutations shows early onset and frequent association with atrial fibrillation and left ventricular noncompaction Heart Rhythm 2017 14 5 717 724 28104484
98. Schweizer PA Schröter J Greiner S The symptom complex of familial sinus node dysfunction and myocardial noncompaction is associated with mutations in the HCN4 channel J Am Coll Cardiol 2014 64 8 757 767 25145518
99. Ponińska J Michalak E Śpiewak M Lutyńska A Płoski R Bilińska ZT A novel HCN4 variant related to familial sinus bradycardia, left ventricular noncompaction, and thoracic aortic aneurysm Pol Arch Intern Med 2021 131 1 70 72 33185997
100. Yokoyama R Kinoshita K Hata Y A mutant HCN4 channel in a family with bradycardia, left bundle branch block, and left ventricular noncompaction Heart Vessels 2018 33 7 802 819 29349559
101. Mysliwiec MR Bresnick EH Lee Y Endothelial Jarid2/Jumonji is required for normal cardiac development and proper Notch1 expression J Biol Chem 2011 286 19 17193 17204 21402699
102. Xu B Li K Liu F Mexiletine shortened QT interval and reduced ventricular arrhythmias in a pedigree of type 2 long QT syndrome combined with left ventricular non-compaction Int Heart J 2021 62 2 427 431 33731522
103. Kharbanda M Hunter A Tennant S Long QT syndrome and left ventricular noncompaction in 4 family members across 2 generations with KCNQ1 mutation Eur J Med Genet 2017 60 5 233 238 28249770
104. Nakashima K Kusakawa I Yamamoto T A left ventricular noncompaction in a patient with long QT syndrome caused by a KCNQ1 mutation: a case report Heart Vessels 2013 28 1 126 129 22354620
105. Kazmirczak F Martin CM Shenoy C Left ventricular noncompaction and cardiogenic shock Circulation 2020 141 8 696 701 32091931
106. Codron P Pautot V Tassin A Abundant electrical myotonia and left ventricular noncompaction: unusual features of Danon disease due to a novel mutation in LAMP2 gene Rev Neurol (Paris) 2019 175 3 201 203 30527948
107. Vatta M Mohapatra B Jimenez S Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction J Am Coll Cardiol 2003 42 11 2014 2027 14662268
108. Xi Y Ai T De Lange E Loss of function of hNav1.5 by a ZASP1 mutation associated with intraventricular conduction disturbances in left ventricular noncompaction Circ Arrhythm Electrophysiol 2012 5 5 1017 1026 22929165
109. Li Z Ai T Samani K A ZASP missense mutation, S196L, leads to cytoskeletal and electrical abnormalities in a mouse model of cardiomyopathy Circ Arrhythm Electrophysiol 2010 3 6 646 656 20852297
110. Pignatelli RH McMahon CJ Dreyer WJ Clinical characterization of left ventricular noncompaction in children: a relatively common form of cardiomyopathy Circulation 2003 108 21 2672 2678 14623814
111. Theis JL Bos JM Bartleson VB Echocardiographic-determined septal morphology in Z-disc hypertrophic cardiomyopathy Biochem Biophys Res Commun 2006 351 4 896 902 17097056
112. Liu Z Shan H Huang J Li N Hou C Pu J A novel lamin A/C gene missense mutation (445 V > E) in immunoglobulin-like fold associated with left ventricular non-compaction Europace 2016 18 4 617 622 25829471
113. Parent JJ Towbin JA Jefferies JL Left ventricular noncompaction in a family with lamin A/C gene mutation Tex Heart Inst J 2015 42 1 73 76 25873806
114. Rankin J Auer-Grumbach M Bagg W Extreme phenotypic diversity and nonpenetrance in families with the LMNA gene mutation R644C Am J Med Genet A 2008 146A 12 1530 1542 18478590
115. Luxán G Casanova JC Martínez-Poveda B Mutations in the NOTCH pathway regulator MIB1 cause left ventricular noncompaction cardiomyopathy Nat Med 2013 19 2 193 201 23314057
116. Piccolo P Attanasio S Secco I MIB2 variants altering NOTCH signalling result in left ventricle hypertrabeculation/non-compaction and are associated with Ménétrier-like gastropathy Hum Mol Genet 2017 26 1 33 43 28013292
117. Eldomery MK Akdemir ZC Vögtle FN MIPEP recessive variants cause a syndrome of left ventricular non-compaction, hypotonia, and infantile death Genome Med 2016 8 1 106 27799064
118. Tanpaiboon P Sloan JL Callahan PF Noncompaction of the ventricular myocardium and hydrops fetalis in cobalamin C disease JIMD Rep 2013 10 33 38 23430797
119. Probst S Oechslin E Schuler P Sarcomere gene mutations in isolated left ventricular noncompaction cardiomyopathy do not predict clinical phenotype Circ Cardiovasc Genet 2011 4 4 367 374 21551322
120. Camuglia AC Younger JF McGaughran J Lo A Atherton JJ Cardiac myosin-binding protein C gene mutation expressed as hypertrophic cardiomyopathy and left ventricular noncompaction within two families: insights from cardiac magnetic resonance in clinical screening: Camuglia MYBPC3 gene mutation and MRI Int J Cardiol 2013 168 3 2950 2952 23642604
121. Liu S Xie Y Zhang H Multiple genetic variants in adolescent patients with left ventricular noncompaction cardiomyopathy Int J Cardiol 2020 302 117 123 31918855
122. Wessels MW Herkert JC Frohn-Mulder IM Compound heterozygous or homozygous truncating MYBPC3 mutations cause lethal cardiomyopathy with features of noncompaction and septal defects Eur J Hum Genet 2015 23 7 922 928 25335496
123. Ripoll Vera T Monserrat Iglesias L Hermida Prieto M The R820W mutation in the MYBPC3 gene, associated with hypertrophic cardiomyopathy in cats, causes hypertrophic cardiomyopathy and left ventricular non-compaction in humans Int J Cardiol 2010 145 2 405 407 20542340
124. Kolokotronis K Kühnisch J Klopocki E Biallelic mutation in MYH7 and MYBPC3 leads to severe cardiomyopathy with left ventricular noncompaction phenotype Hum Mutat 2019 40 8 1101 1114 30924982
125. Schaefer E Helms P Marcellin L Next-generation sequencing (NGS) as a fast molecular diagnosis tool for left ventricular noncompaction in an infant with compound mutations in the MYBPC3 gene Eur J Med Genet 2014 57 4 129 132 24602869
126. Haberer K Buffo-Sequeira I Chudley AE Spriggs E Sergi C A case of an infant with compound heterozygous mutations for hypertrophic cardiomyopathy producing a phenotype of left ventricular noncompaction Can J Cardiol 2014 30 10 1249.e1 3
127. Dellefave LM Pytel P Mewborn S Sarcomere mutations in cardiomyopathy with left ventricular hypertrabeculation Circ Cardiovasc Genet 2009 2 5 442 449 20031619
128. Prada CE Jefferies JL Grenier MA Malonyl coenzyme A decarboxylase deficiency: early dietary restriction and time course of cardiomyopathy Pediatrics 2012 130 2 e456 460 22778304
129. Bainbridge MN Davis EE Choi WY Loss of function mutations in NNT are associated with left ventricular noncompaction Circ Cardiovasc Genet 2015 8 4 544 552 26025024
130. Vermeer AM van Engelen K Postma AV Ebstein anomaly associated with left ventricular noncompaction: an autosomal dominant condition that can be caused by mutations in MYH7 Am J Med Genet C Semin Med Genet 2013 163C 3 178 184 23794396
131. Postma AV van Engelen K van de Meerakker J Mutations in the sarcomere gene MYH7 in Ebstein anomaly Circ Cardiovasc Genet 2011 4 1 43 50 21127202
132. Hirono K Hata Y Ibuki K Yoshimura N Familial Ebstein's anomaly, left ventricular noncompaction, and ventricular septal defect associated with an MYH7 mutation J Thorac Cardiovasc Surg 2014 148 5 e223 226 25444217
133. Latus H Yerebakan C Schranz D Akintuerk H Right ventricular failure from severe pulmonary hypertension after surgery for shone complex: back to fetal physiology with reducting, atrioseptectomy, and bilateral pulmonary arterial banding J Thorac Cardiovasc Surg 2014 148 5 e226 228 25173115
134. Yang J Zhu M Wang Y Whole-exome sequencing identify a new mutation of MYH7 in a Chinese family with left ventricular noncompaction Gene 2015 558 1 138 142 25550050
135. Aksel T Choe YuE Sutton S Ruppel KM Spudich JA Ensemble force changes that result from human cardiac myosin mutations and a small-molecule effector Cell Rep 2015 11 6 910 920 25937279
136. Kaneda T Naruse C Kawashima A A novel beta-myosin heavy chain gene mutation, p.Met531Arg, identified in isolated left ventricular non-compaction in humans, results in left ventricular hypertrophy that progresses to dilation in a mouse model Clin Sci (Lond) 2008 114 6 431 440 17956225
137. Uchiyama T Yoshimura K Kaneko K Surgical repair of left ventricular noncompaction in a patient with a novel mutation of the myosin heavy chain 7 gene Tohoku J Exp Med 2012 228 4 301 304 23117287
138. Sunbul M Ozben B Mutlu B Two different cardiomyopathies in a single patient : hypertrophic cardiomyopathy and left ventricular noncompaction Herz 2013 38 3 313 316 23263242
139. Esposito T Sampaolo S Limongelli G Digenic mutational inheritance of the integrin alpha 7 and the myosin heavy chain 7B genes causes congenital myopathy with left ventricular non-compact cardiomyopathy Orphanet J Rare Dis 2013 8 91 23800289
140. Hoedemaekers YM Cohen-Overbeek TE Frohn-Mulder IM Dooijes D Majoor-Krakauer DF Prenatal ultrasound diagnosis of MYH7 non-compaction cardiomyopathy Ultrasound Obstet Gynecol 2013 41 3 336 339 22859017
141. Ruggiero L Fiorillo C Gibertini S A rare mutation in MYH7 gene occurs with overlapping phenotype Biochem Biophys Res Commun 2015 457 3 262 266 25576864
142. Finsterer J Brandau O Stöllberger C Wallefeld W Laing NG Laccone F Distal myosin heavy chain-7 myopathy due to the novel transition c.5566G>A (p.E1856K) with high interfamilial cardiac variability and putative anticipation Neuromuscul Disord 2014 24 8 721 725 24953931
143. Finsterer J Stöllberger C Hasun M Riedhammer K Wagner M Multisystem myotilinopathy, including myopathy and left ventricular noncompaction, due to the MYOT variant c.179C>T Case Rep Cardiol 2020 2020 5128069 32509353
144. Perrot A Tomasov P Villard E Mutations in NEBL encoding the cardiac Z-disk protein nebulette are associated with various cardiomyopathies Arch Med Sci 2016 12 2 263 278 27186169
145. Palomino Doza J Salguero-Bodes R de la Parte M Arribas-Ynsaurriaga F Association between mutations in the NKX2.5 homeobox, atrial septal defects, ventricular noncompaction and sudden cardiac death Rev Esp Cardiol (Engl Ed) 2018 71 1 53 55 28330612
146. Ouyang P Saarel E Bai Y A de novo mutation in NKX2.5 associated with atrial septal defects, ventricular noncompaction, syncope and sudden death Clin Chim Acta 2011 412 1–2 170 175 20932824
147. Sun H Han L Zhang X Case report: characterization of a novel NONO intronic mutation in a fetus With X-linked syndromic mental retardation-34 Front Genet 2020 11 593688 33304389
148. Reinstein E Tzur S Cohen R Bormans C Behar DM Intellectual disability and non-compaction cardiomyopathy with a de novo NONO mutation identified by exome sequencing Eur J Hum Genet 2016 24 11 1635 1638 27329731
149. Gannon T Perveen R Schlecht H Further delineation of the KAT6B molecular and phenotypic spectrum Eur J Hum Genet 2015 23 9 1165 1170 25424711
150. Sewani M Nugent K Blackburn PR Further delineation of the phenotypic spectrum associated with hemizygous loss-of-function variants in NONO Am J Med Genet A 2020 182 4 652 658 31883306
151. Scott DA Hernandez-Garcia A Azamian MS Congenital heart defects and left ventricular non-compaction in males with loss-of-function variants in NONO J Med Genet 2017 54 1 47 53 27550220
152. Carlston CM Bleyl SB Andrews A Expanding the genetic and clinical spectrum of the NONO-associated X-linked intellectual disability syndrome Am J Med Genet A 2019 179 5 792 796 30773818
153. Sun H Zhou X Hao X Zhang Y Zhang H He Y Characteristics of cardiac phenotype in prenatal familial cases with NONO mutations Circ Genom Precis Med 2020 13 3 e002847 32397791
154. Yang J Bücker S Jungblut B Inhibition of Notch2 by Numb/Numblike controls myocardial compaction in the heart Cardiovasc Res 2012 96 2 276 285 22865640
155. Rowland TJ Graw SL Sweet ME Gigli M Taylor MR Mestroni L Obscurin variants in patients with left ventricular noncompaction J Am Coll Cardiol 2016 68 20 2237 2238 27855815
156. Muhammad E Levitas A Singh SR PLEKHM2 mutation leads to abnormal localization of lysosomes, impaired autophagy flux and associates with recessive dilated cardiomyopathy and left ventricular noncompaction Hum Mol Genet 2015 24 25 7227 7240 26464484
157. Long PA Evans JM Olson TM Diagnostic yield of whole exome sequencing in pediatric dilated cardiomyopathy J Cardiovasc Dev Dis 2017 4 3 11
158. Delplancq G Tarris G Vitobello A Cardiomyopathy due to PRDM16 mutation: first description of a fetal presentation, with possible modifier genes Am J Med Genet C Semin Med Genet 2020 184 1 129 135 31965688
159. Kim K Kang MG Park HW A rare case of left ventricular noncompaction in LEOPARD syndrome J Cardiovasc Ultrasound 2018 26 1 43 44 29629024
160. Sun Q Guo J Hao C Whole-exome sequencing reveals two de novo variants in the RBM20 gene in two Chinese patients with left ventricular non-compaction cardiomyopathy Pediatr Investig 2020 4 1 11 16 32851336
161. Leung C Engineer A Kim MY Lu X Feng Q Myocardium-specific deletion of Rac1 causes ventricular noncompaction and outflow tract defects J Cardiovasc Dev Dis. 2021 8 3 29 33804107
162. Martinez HR Niu MC Sutton VR Pignatelli R Vatta M Jefferies JL Coffin–Lowry syndrome and left ventricular noncompaction cardiomyopathy with a restrictive pattern Am J Med Genet A 2011 155A 12 3030 3034 22009732
163. Bhuiyan ZA van den Berg MP van Tintelen JP Expanding spectrum of human RYR2-related disease: new electrocardiographic, structural, and genetic features Circulation 2007 116 14 1569 1576 17875969
164. Campbell MJ Czosek RJ Hinton RB Miller EM Exon 3 deletion of ryanodine receptor causes left ventricular noncompaction, worsening catecholaminergic polymorphic ventricular tachycardia, and sudden cardiac arrest Am J Med Genet A 2015 167A 9 2197 2200 26018045
165. Ohno S Omura M Kawamura M Exon 3 deletion of RYR2 encoding cardiac ryanodine receptor is associated with left ventricular non-compaction Europace 2014 16 11 1646 1654 24394973
166. Roston TM Guo W Krahn AD A novel RYR2 loss-of-function mutation (I4855M) is associated with left ventricular non-compaction and atypical catecholaminergic polymorphic ventricular tachycardia J Electrocardiol 2017 50 2 227 233 27646203
167. Shan L Makita N Xing Y SCN5A variants in Japanese patients with left ventricular noncompaction and arrhythmia Mol Genet Metab 2008 93 4 468 474 18368697
168. Alston CL Ceccatelli Berti C Blakely EL A recessive homozygous p.Asp92Gly SDHD mutation causes prenatal cardiomyopathy and a severe mitochondrial complex II deficiency Hum Genet 2015 134 8 869 879 26008905
169. Li L Huang L Lin S Luo Y Fang Q Discordant phenotypes in monozygotic twins with 16p11.2 microdeletions including the SH2B1 gene Am J Med Genet A 2017 173 8 2284 2288 28544142
170. Lin W Li D Cheng L Zinc transporter Slc39a8 is essential for cardiac ventricular compaction J Clin Invest 2018 128 2 826 833 29337306
171. Wenger TL Chow P Randle SC Novel findings of left ventricular non-compaction cardiomyopathy, microform cleft lip and poor vision in patient with SMC1A-associated Cornelia de Lange syndrome Am J Med Genet A 2017 173 2 414 420 28102598
172. Sun H Yu S Zhou X Han L Zhang H He Y Expanding the phenotype of STRA6-related disorder to include left ventricular non-compaction Mol Genet Genomic Med 2020 8 9 e1377 32597569
173. Brady AN Shehata BM Fernhoff PM X-linked fetal cardiomyopathy caused by a novel mutation in the TAZ gene Prenat Diagn 2006 26 5 462 465 16548007
174. Chang B Momoi N Shan L Gonadal mosaicism of a TAZ (G4.5) mutation in a Japanese family with Barth syndrome and left ventricular noncompaction Mol Genet Metab 2010 100 2 198 203 20303308
175. Momoi N Chang B Takeda I Aoyagi Y Endo K Ichida F Differing clinical courses and outcomes in two siblings with Barth syndrome and left ventricular noncompaction Eur J Pediatr 2012 171 3 515 520 21987083
176. Kenton AB Sanchez X Coveler KJ Isolated left ventricular noncompaction is rarely caused by mutations in G4.5, alpha-dystrobrevin and FK Binding Protein-12 Mol Genet Metab 2004 82 2 162 166 15172004
177. Wang J Guo Y Huang M Identification of TAZ mutations in pediatric patients with cardiomyopathy by targeted next-generation sequencing in a Chinese cohort Orphanet J Rare Dis 2017 12 1 26 28183324
178. Chen R Tsuji T Ichida F Mutation analysis of the G4.5 gene in patients with isolated left ventricular noncompaction Mol Genet Metab 2002 77 4 319 325 12468278
179. Ronvelia D Greenwood J Platt J Hakim S Zaragoza MV Intrafamilial variability for novel TAZ gene mutation: Barth syndrome with dilated cardiomyopathy and heart failure in an infant and left ventricular noncompaction in his great-uncle Mol Genet Metab 2012 107 3 428 432 23031367
180. Karkucinska-Wieckowska A Trubicka J Werner B Left ventricular noncompaction (LVNC) and low mitochondrial membrane potential are specific for Barth syndrome J Inherit Metab Dis 2013 36 6 929 937 23361305
181. Ross SB Bagnall RD Yeates L Sy RW Semsarian C Holt-Oram syndrome in two families diagnosed with left ventricular noncompaction and conduction disease Heart Rhythm Case Rep 2018 4 4 146 151
182. Miyao N Hata Y Izumi H TBX5 R264K acts as a modifier to develop dilated cardiomyopathy in mice independently of T-box pathway PLoS ONE 2020 15 4 e0227393 32236096
183. Kodo K Ong SG Jahanbani F iPSC-derived cardiomyocytes reveal abnormal TGF-β signalling in left ventricular non-compaction cardiomyopathy Nat Cell Biol 2016 18 10 1031 1042 27642787
184. Hirono K Ichida F Nishio N Mitochondrial complex deficiency by novel compound heterozygous TMEM70 variants and correlation with developmental delay, undescended testicle, and left ventricular noncompaction in a Japanese patient: a case report Clin Case Rep 2019 7 3 553 557 30899493
185. Fujino M Tsuda E Hirono K The TNNI3 Arg192His mutation in a 13-year-old girl with left ventricular noncompaction J Cardiol Cases 2018 18 1 33 36 30279906
186. Luedde M Ehlermann P Weichenhan D Severe familial left ventricular non-compaction cardiomyopathy due to a novel troponin T (TNNT2) mutation Cardiovasc Res 2010 86 3 452 460 20083571
187. Mogensen J Murphy RT Shaw T Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy J Am Coll Cardiol 2004 44 10 2033 2040 15542288
188. Chang B Nishizawa T Furutani M Identification of a novel TPM1 mutation in a family with left ventricular noncompaction and sudden death Mol Genet Metab 2011 102 2 200 206 20965760
189. Nijak A Alaerts M Kuiperi C Left ventricular non-compaction with Ebstein anomaly attributed to a TPM1 mutation Eur J Med Genet 2018 61 1 8 10 29024827
190. Kelle AM Bentley SJ Rohena LO Cabalka AK Olson TM Ebstein anomaly, left ventricular non-compaction, and early onset heart failure associated with a de novo α-tropomyosin gene mutation Am J Med Genet A 2016 170 8 2186 2190 27177193
191. Hastings R de Villiers CP Hooper C Combination of whole genome sequencing, linkage, and functional studies implicates a missense mutation in titin as a cause of autosomal dominant cardiomyopathy with features of left ventricular noncompaction Circ Cardiovasc Genet 2016 9 5 426 435 27625337
192. Chauveau C Bonnemann CG Julien C Recessive TTN truncating mutations define novel forms of core myopathy with heart disease Hum Mol Genet 2014 23 4 980 991 24105469
193. Chang B Gorbea C Lezin G 14-3-3ε gene variants in a Japanese patient with left ventricular noncompaction and hypoplasia of the corpus callosum Gene 2013 515 1 173 180 23266643
194. Tang S Batra A Zhang Y Ebenroth ES Huang T Left ventricular noncompaction is associated with mutations in the mitochondrial genome Mitochondrion 2010 10 4 350 357 20211276
195. Zarrouk Mahjoub S Mehri S Ourda F Transition m.3308T>C in the ND1 gene is associated with left ventricular hypertrabeculation/noncompaction Cardiology 2011 118 3 153 158 21625124
196. Zarrouk Mahjoub S Mehri S Ourda F Pathogenicity of the transition m.3308T>C in left ventricular hypertrabeculation/noncompaction Cardiology 2012 122 2 116 118 22777278

